https://trial.medpath.com/news/hct-asct-confirmed-as-standard-of-care-consolidation-for-primary-cns-lymphoma-in-landmark-phase-iii-trial 2026-07-31T20:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hct-asct-confirmed-as-standard-of-care-consolidation-for-primary-cns-lymphoma-in-landmark-phase-iii-trial 2026-07-31T20:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/shanghai-industry-association-issues-first-ever-technical-standard-for-plant-derived-exosome-like-nanovesicles 2026-07-31T20:11:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shanghai-industry-association-issues-first-ever-technical-standard-for-plant-derived-exosome-like-nanovesicles 2026-07-31T20:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-builds-mrna-lnp-and-adc-capabilities-to-advance-oncology-and-virology-pipelines 2026-07-31T20:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-builds-mrna-lnp-and-adc-capabilities-to-advance-oncology-and-virology-pipelines 2026-07-31T20:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/prof-fabrice-barlesi-reappointed-as-director-general-of-gustave-roussy-for-a-second-five-year-term 2026-07-31T19:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prof-fabrice-barlesi-reappointed-as-director-general-of-gustave-roussy-for-a-second-five-year-term 2026-07-31T19:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/ketamine-induces-sex-specific-neuroplasticity-through-microglial-activation-in-female-mice 2026-07-31T19:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketamine-induces-sex-specific-neuroplasticity-through-microglial-activation-in-female-mice 2026-07-31T19:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-clinical-research-recruitment-program-doubles-study-inquiries-through-website-redesign 2026-07-31T19:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-clinical-research-recruitment-program-doubles-study-inquiries-through-website-redesign 2026-07-31T19:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyaku-exercises-30-million-u-s-commercialization-option-for-ab2-bio-s-tadekinig-alfa-in-ultra-rare-pediatric-hyperinflammatory-syndrome 2026-07-31T17:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyaku-exercises-30-million-u-s-commercialization-option-for-ab2-bio-s-tadekinig-alfa-in-ultra-rare-pediatric-hyperinflammatory-syndrome 2026-07-31T17:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/whx-osaka-positions-osaka-as-a-global-hub-for-healthy-longevity-and-life-sciences-innovation 2026-07-31T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whx-osaka-positions-osaka-as-a-global-hub-for-healthy-longevity-and-life-sciences-innovation 2026-07-31T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-clues-emerge-for-car-t-toxicity-risk-opening-path-to-safer-cell-therapies 2026-07-31T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-clues-emerge-for-car-t-toxicity-risk-opening-path-to-safer-cell-therapies 2026-07-31T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ai-model-predicts-tp53-mutations-and-survival-across-32-cancer-types-from-routine-pathology-slides 2026-07-31T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ai-model-predicts-tp53-mutations-and-survival-across-32-cancer-types-from-routine-pathology-slides 2026-07-31T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/paclitaxel-coated-balloon-matches-rapamycin-eluting-stent-in-de-novo-small-vessel-coronary-disease 2026-07-31T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paclitaxel-coated-balloon-matches-rapamycin-eluting-stent-in-de-novo-small-vessel-coronary-disease 2026-07-31T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-s-jnj-5120-pipe-307-misses-primary-endpoint-in-phase-2-moonlight-1-depression-trial 2026-07-31T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-s-jnj-5120-pipe-307-misses-primary-endpoint-in-phase-2-moonlight-1-depression-trial 2026-07-31T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-therapeutics-reports-q2-loss-of-21-9-million-missing-wall-street-estimates 2026-07-31T14:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-therapeutics-reports-q2-loss-of-21-9-million-missing-wall-street-estimates 2026-07-31T14:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/large-us-echo-cohort-study-finds-no-overall-link-between-prenatal-water-fluoride-and-children-s-behavior 2026-07-31T14:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-us-echo-cohort-study-finds-no-overall-link-between-prenatal-water-fluoride-and-children-s-behavior 2026-07-31T14:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-acquires-monash-s-8-fold-lnp-targeting-technology-to-solve-in-vivo-car-t-s-liver-delivery-problem 2026-07-31T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/create-medicines-acquires-monash-s-8-fold-lnp-targeting-technology-to-solve-in-vivo-car-t-s-liver-delivery-problem 2026-07-31T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-ziltivekimab-fails-phase-3-zeus-trial-missing-primary-mace-endpoint-in-cardiovascular-disease 2026-07-31T14:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-ziltivekimab-fails-phase-3-zeus-trial-missing-primary-mace-endpoint-in-cardiovascular-disease 2026-07-31T14:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/multimodal-ai-in-surgical-oncology-shows-promise-but-lacks-prospective-evidence-review-finds 2026-07-31T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multimodal-ai-in-surgical-oncology-shows-promise-but-lacks-prospective-evidence-review-finds 2026-07-31T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-to-launch-integrated-digital-drug-regulatory-platform-within-18-months-piloting-ai-to-slash-processing-times 2026-07-31T13:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-to-launch-integrated-digital-drug-regulatory-platform-within-18-months-piloting-ai-to-slash-processing-times 2026-07-31T13:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-therapeutics-secures-u-s-fda-ind-clearance-for-first-in-class-sarna-therapy-rag-1c-targeting-proliferative-vitreoretinopathy 2026-07-31T12:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-therapeutics-secures-u-s-fda-ind-clearance-for-first-in-class-sarna-therapy-rag-1c-targeting-proliferative-vitreoretinopathy 2026-07-31T12:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/smart-materials-and-devices-for-stimuli-responsive-drug-delivery-advancing-precision-therapeutics 2026-07-31T12:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-materials-and-devices-for-stimuli-responsive-drug-delivery-advancing-precision-therapeutics 2026-07-31T12:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/vector-centre-advances-mrna-vaccine-pipeline-for-hiv-monkeypox-and-tick-borne-encephalitis 2026-07-31T11:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vector-centre-advances-mrna-vaccine-pipeline-for-hiv-monkeypox-and-tick-borne-encephalitis 2026-07-31T11:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/impact-therapeutics-licenses-parp-inhibitor-senaparib-to-pharmanovia-in-deal-worth-up-to-eur423-5-million 2026-07-31T10:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-therapeutics-licenses-parp-inhibitor-senaparib-to-pharmanovia-in-deal-worth-up-to-eur423-5-million 2026-07-31T10:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/dual-cd19-cd70-car-t-therapy-shows-superior-lymphoma-control-in-preclinical-models-cd70-identified-as-relapse-biomarker 2026-07-31T10:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-cd19-cd70-car-t-therapy-shows-superior-lymphoma-control-in-preclinical-models-cd70-identified-as-relapse-biomarker 2026-07-31T10:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-oncology-pipeline-surge-firefly-bio-acquisition-sail-biomedicines-car-t-deal-and-ottava-robotic-system-fda-authorization 2026-07-31T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-oncology-pipeline-surge-firefly-bio-acquisition-sail-biomedicines-car-t-deal-and-ottava-robotic-system-fda-authorization 2026-07-31T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/uams-acquires-proton-center-of-arkansas-securing-long-term-access-to-advanced-cancer-therapy 2026-07-31T08:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uams-acquires-proton-center-of-arkansas-securing-long-term-access-to-advanced-cancer-therapy 2026-07-31T08:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-advances-in-pediatric-sarcoma-ntrk-targeted-therapy-and-multimodal-care-transform-outcomes 2026-07-31T06:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-advances-in-pediatric-sarcoma-ntrk-targeted-therapy-and-multimodal-care-transform-outcomes 2026-07-31T06:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/kansas-hospitals-expand-access-to-fda-approved-anti-amyloid-infusion-therapies-for-early-alzheimer-s-disease 2026-07-31T06:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kansas-hospitals-expand-access-to-fda-approved-anti-amyloid-infusion-therapies-for-early-alzheimer-s-disease 2026-07-31T06:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-advances-escharex-phase-iii-valu-trial-as-updated-u-s-market-assessment-tops-1-billion 2026-07-31T06:11:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediwound-advances-escharex-phase-iii-valu-trial-as-updated-u-s-market-assessment-tops-1-billion 2026-07-31T06:11:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-unveils-fy-2027-user-fee-rates-pdufa-revenue-target-rises-6-mdufa-jumps-14 2026-07-31T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-unveils-fy-2027-user-fee-rates-pdufa-revenue-target-rises-6-mdufa-jumps-14 2026-07-31T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/ensifentrine-improves-lung-function-in-chinese-patients-with-copd-enhance-china-study 2026-07-31T06:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensifentrine-improves-lung-function-in-chinese-patients-with-copd-enhance-china-study 2026-07-31T06:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-closes-upsized-220-8-million-ipo-to-advance-oral-therapy-for-obstructive-sleep-apnea 2026-07-31T03:20:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apnimed-closes-upsized-220-8-million-ipo-to-advance-oral-therapy-for-obstructive-sleep-apnea 2026-07-31T03:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-de-novo-authorization-to-caristo-s-cari-heart-first-ai-powered-coronary-inflammation-quantification-technology 2026-07-31T03:20:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-de-novo-authorization-to-caristo-s-cari-heart-first-ai-powered-coronary-inflammation-quantification-technology 2026-07-31T03:20:19+00:00 hourly 0.9 https://trial.medpath.com/news/squires-erases-ptab-ax-of-dermatology-ip-upheld-at-itc 2026-07-31T03:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/squires-erases-ptab-ax-of-dermatology-ip-upheld-at-itc 2026-07-31T03:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/fructose-identified-as-surprise-driver-of-ovarian-cancer-metastasis-after-chemotherapy 2026-07-31T03:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fructose-identified-as-surprise-driver-of-ovarian-cancer-metastasis-after-chemotherapy 2026-07-31T03:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cleared-single-port-robotic-nipple-sparing-mastectomy-performed-at-community-hospital-for-the-first-time 2026-07-31T03:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cleared-single-port-robotic-nipple-sparing-mastectomy-performed-at-community-hospital-for-the-first-time 2026-07-31T03:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/federal-medical-scientists-turn-to-llms-as-research-co-pilots-across-fda-nci-and-argonne 2026-07-31T03:15:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-medical-scientists-turn-to-llms-as-research-co-pilots-across-fda-nci-and-argonne 2026-07-31T03:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/biopharmaceutical-pat-market-projected-to-reach-4-32-billion-by-2031-driven-by-vaccine-manufacturing-and-asia-pacific-expansion 2026-07-31T03:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharmaceutical-pat-market-projected-to-reach-4-32-billion-by-2031-driven-by-vaccine-manufacturing-and-asia-pacific-expansion 2026-07-31T03:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-uncover-two-mysterious-ghost-ancestors-hiding-in-modern-human-dna 2026-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-uncover-two-mysterious-ghost-ancestors-hiding-in-modern-human-dna 2026-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anti-virulence-agents-targeting-bacterial-quorum-sensing-emerge-as-resistance-sparing-strategy-in-post-antibiotic-era 2026-07-30T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-virulence-agents-targeting-bacterial-quorum-sensing-emerge-as-resistance-sparing-strategy-in-post-antibiotic-era 2026-07-30T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-to-report-second-quarter-2026-financial-results-on-august-6 2026-07-30T22:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prothena-to-report-second-quarter-2026-financial-results-on-august-6 2026-07-30T22:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/calls-mount-for-reform-of-south-korean-dental-schools-clinical-training-patient-recruitment-system 2026-07-30T22:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calls-mount-for-reform-of-south-korean-dental-schools-clinical-training-patient-recruitment-system 2026-07-30T22:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/measles-rna-detected-in-anchorage-wastewater-prompting-vaccination-warnings-amid-low-immunization-rates 2026-07-30T22:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-rna-detected-in-anchorage-wastewater-prompting-vaccination-warnings-amid-low-immunization-rates 2026-07-30T22:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/hokkaido-university-scientists-develop-e-mito-a-surface-engineered-mitochondrial-delivery-system-for-organelle-based-therapeutics 2026-07-30T22:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hokkaido-university-scientists-develop-e-mito-a-surface-engineered-mitochondrial-delivery-system-for-organelle-based-therapeutics 2026-07-30T22:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-clinical-trials-symposium-2026-asia-charts-path-to-become-global-epicenter-for-clinical-research 2026-07-30T22:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-clinical-trials-symposium-2026-asia-charts-path-to-become-global-epicenter-for-clinical-research 2026-07-30T22:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-revives-maximum-strength-claims-in-oral-phenylephrine-decongestant-false-advertising-litigation 2026-07-30T22:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-revives-maximum-strength-claims-in-oral-phenylephrine-decongestant-false-advertising-litigation 2026-07-30T22:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-r-d-workforce-trends-phrma-and-usamriid-employment-data-reveal-shifting-global-footprints-in-2026 2026-07-30T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-r-d-workforce-trends-phrma-and-usamriid-employment-data-reveal-shifting-global-footprints-in-2026 2026-07-30T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-restore-lost-protein-bmp3-to-reverse-pulmonary-arterial-hypertension-in-preclinical-models 2026-07-30T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-restore-lost-protein-bmp3-to-reverse-pulmonary-arterial-hypertension-in-preclinical-models 2026-07-30T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/virginia-catalyst-awards-2-4-million-to-advance-surgical-hydrogel-trauma-resuscitation-drug-and-ai-enabled-fracture-healing-device-toward-human-trials 2026-07-30T21:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virginia-catalyst-awards-2-4-million-to-advance-surgical-hydrogel-trauma-resuscitation-drug-and-ai-enabled-fracture-healing-device-toward-human-trials 2026-07-30T21:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/early-remdesivir-tied-to-reduced-graft-loss-and-cardiovascular-events-in-kidney-transplant-recipients-with-acute-covid-19 2026-07-30T21:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-remdesivir-tied-to-reduced-graft-loss-and-cardiovascular-events-in-kidney-transplant-recipients-with-acute-covid-19 2026-07-30T21:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/meitheal-pharmaceuticals-announces-fda-approval-of-garzulystm-insulin-aspart-fsan-a-biosimilar-to-novolog 2026-07-30T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meitheal-pharmaceuticals-announces-fda-approval-of-garzulystm-insulin-aspart-fsan-a-biosimilar-to-novolog 2026-07-30T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-uc-san-diego-18-million-to-establish-quantum-materials-research-center 2026-07-30T20:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-uc-san-diego-18-million-to-establish-quantum-materials-research-center 2026-07-30T20:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/opportunistic-salpingectomy-reduces-ovarian-cancer-risk-by-78-experts-call-it-a-no-brainer 2026-07-30T19:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opportunistic-salpingectomy-reduces-ovarian-cancer-risk-by-78-experts-call-it-a-no-brainer 2026-07-30T19:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/recovryai-completes-patient-phase-of-pivotal-trial-for-ai-powered-postoperative-virtual-care-assistant 2026-07-30T18:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recovryai-completes-patient-phase-of-pivotal-trial-for-ai-powered-postoperative-virtual-care-assistant 2026-07-30T18:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/openabe-gene-editor-achieves-up-to-36-fold-efficiency-gain-overcoming-ai-designed-editor-limitations 2026-07-30T18:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openabe-gene-editor-achieves-up-to-36-fold-efficiency-gain-overcoming-ai-designed-editor-limitations 2026-07-30T18:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/nano-flow-cytometry-advances-single-particle-characterization-of-targeted-lipid-nanoparticles-for-extrahepatic-delivery 2026-07-30T18:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nano-flow-cytometry-advances-single-particle-characterization-of-targeted-lipid-nanoparticles-for-extrahepatic-delivery 2026-07-30T18:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/tvardi-therapeutics-selects-ulcerative-colitis-as-initial-indication-for-stat3-inhibitor-tti-109-plans-2027-trial 2026-07-30T18:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tvardi-therapeutics-selects-ulcerative-colitis-as-initial-indication-for-stat3-inhibitor-tti-109-plans-2027-trial 2026-07-30T18:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/probiotic-derived-metabolite-10-hsa-repairs-hiv-gut-damage-and-boosts-art-response-in-preclinical-model 2026-07-30T18:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probiotic-derived-metabolite-10-hsa-repairs-hiv-gut-damage-and-boosts-art-response-in-preclinical-model 2026-07-30T18:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-s-dm199-rinvecalinase-alfa-advances-in-preeclampsia-and-stroke-phase-2-data-regulatory-milestones-and-market-outlook 2026-07-30T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamedica-s-dm199-rinvecalinase-alfa-advances-in-preeclampsia-and-stroke-phase-2-data-regulatory-milestones-and-market-outlook 2026-07-30T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-investigates-why-female-patients-experience-more-severe-oral-mucositis-after-head-and-neck-cancer-radiation 2026-07-30T16:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-investigates-why-female-patients-experience-more-severe-oral-mucositis-after-head-and-neck-cancer-radiation 2026-07-30T16:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/lencabo-trial-reveals-catabolic-trade-off-for-lenvatinib-everolimus-in-metastatic-ccrcc 2026-07-30T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lencabo-trial-reveals-catabolic-trade-off-for-lenvatinib-everolimus-in-metastatic-ccrcc 2026-07-30T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/mercantile-life-science-ventures-and-big-idea-ventures-invest-in-maia-fertility-to-advance-ferizymetm-platform 2026-07-30T16:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercantile-life-science-ventures-and-big-idea-ventures-invest-in-maia-fertility-to-advance-ferizymetm-platform 2026-07-30T16:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-mmi-to-expand-enrollment-in-pioneering-robotic-microsurgery-trial-for-alzheimer-s-disease 2026-07-30T16:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-mmi-to-expand-enrollment-in-pioneering-robotic-microsurgery-trial-for-alzheimer-s-disease 2026-07-30T16:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/ai-protein-design-market-to-reach-13-70-billion-by-2035-as-generative-models-reshape-drug-discovery 2026-07-30T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-protein-design-market-to-reach-13-70-billion-by-2035-as-generative-models-reshape-drug-discovery 2026-07-30T16:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/orexin-receptor-agonists-herald-a-new-era-for-narcolepsy-type-1-treatment 2026-07-30T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orexin-receptor-agonists-herald-a-new-era-for-narcolepsy-type-1-treatment 2026-07-30T16:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/magic-molecule-launches-fda-cleared-hypochlorous-acid-skin-spray-in-more-than-4500-walmart-stores 2026-07-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magic-molecule-launches-fda-cleared-hypochlorous-acid-skin-spray-in-more-than-4500-walmart-stores 2026-07-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chandigarh-university-biotech-and-pharmacy-students-secure-178-placements-with-leading-pharma-companies 2026-07-30T14:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chandigarh-university-biotech-and-pharmacy-students-secure-178-placements-with-leading-pharma-companies 2026-07-30T14:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-establishes-first-pic-s-gmp-certified-stem-cell-manufacturing-facility-advancing-cell-and-gene-therapy-ecosystem 2026-07-30T14:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-establishes-first-pic-s-gmp-certified-stem-cell-manufacturing-facility-advancing-cell-and-gene-therapy-ecosystem 2026-07-30T14:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyaku-exercises-option-for-ab2-bio-s-tadekinig-alfa-securing-u-s-commercialization-rights-for-rare-autoinflammatory-diseases 2026-07-30T14:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyaku-exercises-option-for-ab2-bio-s-tadekinig-alfa-securing-u-s-commercialization-rights-for-rare-autoinflammatory-diseases 2026-07-30T14:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-launches-industry-s-first-drug-discovery-and-development-benchmark-as-a-service-to-validate-ai-models-against-real-world-pharmaceutical-data 2026-07-30T14:17:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-launches-industry-s-first-drug-discovery-and-development-benchmark-as-a-service-to-validate-ai-models-against-real-world-pharmaceutical-data 2026-07-30T14:17:49+00:00 hourly 0.9 https://trial.medpath.com/news/direct-to-patient-models-reshape-pharma-s-commercial-strategy-as-nine-major-companies-launch-branded-drug-channels 2026-07-30T13:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/direct-to-patient-models-reshape-pharma-s-commercial-strategy-as-nine-major-companies-launch-branded-drug-channels 2026-07-30T13:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/sustained-heatwaves-driving-increased-risk-of-infectious-diseases-across-europe-ecdc-warns 2026-07-30T12:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sustained-heatwaves-driving-increased-risk-of-infectious-diseases-across-europe-ecdc-warns 2026-07-30T12:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/global-botulinum-toxin-market-poised-to-reach-29-billion-by-2035-driven-by-aesthetic-democratization-and-expanding-therapeutic-indications 2026-07-30T11:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-botulinum-toxin-market-poised-to-reach-29-billion-by-2035-driven-by-aesthetic-democratization-and-expanding-therapeutic-indications 2026-07-30T11:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-relation-therapeutics-sign-up-to-110-million-ai-drug-discovery-deal 2026-07-30T11:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-relation-therapeutics-sign-up-to-110-million-ai-drug-discovery-deal 2026-07-30T11:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-appoints-dr-anders-ullman-to-board-as-it-advances-pipeline-in-cancer-cachexia-and-muscle-wasting 2026-07-30T11:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-appoints-dr-anders-ullman-to-board-as-it-advances-pipeline-in-cancer-cachexia-and-muscle-wasting 2026-07-30T11:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/fierce-pharma-week-europe-launches-in-basel-for-2027-targeting-cross-functional-pharma-leadership 2026-07-30T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fierce-pharma-week-europe-launches-in-basel-for-2027-targeting-cross-functional-pharma-leadership 2026-07-30T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-s-xfg-adapted-covid-19-vaccine-wins-fda-approval-for-at-risk-adults 2026-07-30T10:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-s-xfg-adapted-covid-19-vaccine-wins-fda-approval-for-at-risk-adults 2026-07-30T10:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/nara-smith-credits-couples-therapy-for-navigating-daughter-s-cancer-journey 2026-07-30T10:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nara-smith-credits-couples-therapy-for-navigating-daughter-s-cancer-journey 2026-07-30T10:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/pregnancy-after-car-t-cell-therapy-new-data-on-fertility-outcomes 2026-07-30T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pregnancy-after-car-t-cell-therapy-new-data-on-fertility-outcomes 2026-07-30T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-surpasses-enrollment-midpoint-in-nanopulse-af-pivotal-trial-for-nanosecond-pulsed-field-ablation 2026-07-30T10:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-biosciences-surpasses-enrollment-midpoint-in-nanopulse-af-pivotal-trial-for-nanosecond-pulsed-field-ablation 2026-07-30T10:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-reports-30-4m-h1-2026-revenue-advances-accrufer-r-into-phase-ii-pah-trial-in-japan 2026-07-30T09:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-reports-30-4m-h1-2026-revenue-advances-accrufer-r-into-phase-ii-pah-trial-in-japan 2026-07-30T09:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/the-systemic-bottleneck-why-biopharma-s-drug-development-crisis-is-organizational-not-scientific 2026-07-30T09:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-systemic-bottleneck-why-biopharma-s-drug-development-crisis-is-organizational-not-scientific 2026-07-30T09:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/teclistamab-enables-kidney-transplant-in-patient-with-zero-compatibility-odds-published-in-nejm 2026-07-30T09:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teclistamab-enables-kidney-transplant-in-patient-with-zero-compatibility-odds-published-in-nejm 2026-07-30T09:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/leadership-changes-at-novartis-india-two-directors-step-down 2026-07-30T07:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leadership-changes-at-novartis-india-two-directors-step-down 2026-07-30T07:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-to-present-at-canaccord-genuity-46th-annual-growth-conference 2026-07-30T07:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-to-present-at-canaccord-genuity-46th-annual-growth-conference 2026-07-30T07:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-authorizes-pfizer-biontech-xfg-adapted-covid-19-vaccine-for-2026-2027-season 2026-07-30T07:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-authorizes-pfizer-biontech-xfg-adapted-covid-19-vaccine-for-2026-2027-season 2026-07-30T07:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-upgrades-2026-guidance-on-23-5-sales-growth-positive-phase-iii-readouts-and-pipeline-building-acquisitions 2026-07-30T07:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-upgrades-2026-guidance-on-23-5-sales-growth-positive-phase-iii-readouts-and-pipeline-building-acquisitions 2026-07-30T07:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/in-bed-cycling-plus-protein-supplementation-fails-to-improve-physical-recovery-in-icu-patients-with-acute-respiratory-failure-nexis-trial-finds 2026-07-30T06:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-bed-cycling-plus-protein-supplementation-fails-to-improve-physical-recovery-in-icu-patients-with-acute-respiratory-failure-nexis-trial-finds 2026-07-30T06:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/isothermal-nucleic-acid-amplification-technology-market-to-reach-usd-16-7-billion-by-2034 2026-07-30T06:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isothermal-nucleic-acid-amplification-technology-market-to-reach-usd-16-7-billion-by-2034 2026-07-30T06:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-to-sell-neuronos-stake-to-univo-in-exchange-for-equity-and-up-to-32-5-million-in-milestone-payments 2026-07-30T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-to-sell-neuronos-stake-to-univo-in-exchange-for-equity-and-up-to-32-5-million-in-milestone-payments 2026-07-30T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/jeil-pharmaceutical-s-dual-sglt-1-2-inhibitor-jp-2266-shows-significant-hba1c-reduction-in-phase-2-diabetes-trial 2026-07-30T02:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeil-pharmaceutical-s-dual-sglt-1-2-inhibitor-jp-2266-shows-significant-hba1c-reduction-in-phase-2-diabetes-trial 2026-07-30T02:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/new-ai-powered-home-test-uses-thigh-length-to-detect-type-2-diabetes-and-prediabetes 2026-07-30T02:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ai-powered-home-test-uses-thigh-length-to-detect-type-2-diabetes-and-prediabetes 2026-07-30T02:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/fauci-invokes-fifth-amendment-over-100-times-in-contentious-senate-hearing-paul-seeks-contempt-charges 2026-07-30T02:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fauci-invokes-fifth-amendment-over-100-times-in-contentious-senate-hearing-paul-seeks-contempt-charges 2026-07-30T02:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/world-hepatitis-day-research-topics-highlight-gaps-in-diagnosis-treatment-access-and-pediatric-elimination-of-viral-hepatitis 2026-07-30T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-hepatitis-day-research-topics-highlight-gaps-in-diagnosis-treatment-access-and-pediatric-elimination-of-viral-hepatitis 2026-07-30T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvia-therapeutics-raises-8-million-seed-round-to-advance-mitochondrial-therapy-ati-105-toward-clinical-trials 2026-07-30T01:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvia-therapeutics-raises-8-million-seed-round-to-advance-mitochondrial-therapy-ati-105-toward-clinical-trials 2026-07-30T01:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-veterinary-conference-2026-to-spotlight-one-health-professional-wellness-and-human-animal-bond-research 2026-07-30T01:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-veterinary-conference-2026-to-spotlight-one-health-professional-wellness-and-human-animal-bond-research 2026-07-30T01:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/boston-researchers-advance-toward-diagnosing-cte-in-living-patients-enlisting-former-nfl-quarterback-matt-hasselbeck 2026-07-30T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-researchers-advance-toward-diagnosing-cte-in-living-patients-enlisting-former-nfl-quarterback-matt-hasselbeck 2026-07-30T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/latigo-biotherapeutics-posts-positive-phase-2-data-for-non-opioid-pain-drug-challenging-vertex-s-market-position 2026-07-30T00:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latigo-biotherapeutics-posts-positive-phase-2-data-for-non-opioid-pain-drug-challenging-vertex-s-market-position 2026-07-30T00:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/cryopreserved-umbilical-cord-allografts-show-pain-reduction-in-cervical-paraspinal-muscle-degeneration-31-patient-study 2026-07-30T00:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cryopreserved-umbilical-cord-allografts-show-pain-reduction-in-cervical-paraspinal-muscle-degeneration-31-patient-study 2026-07-30T00:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-medications-expert-perspectives-on-efficacy-candidates-and-long-term-weight-maintenance 2026-07-30T00:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-medications-expert-perspectives-on-efficacy-candidates-and-long-term-weight-maintenance 2026-07-30T00:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/manifest-io-launches-landmark-uk-wide-prospective-study-to-unravel-immunotherapy-response-and-toxicity 2026-07-30T00:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manifest-io-launches-landmark-uk-wide-prospective-study-to-unravel-immunotherapy-response-and-toxicity 2026-07-30T00:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-secures-nearly-1-8-billion-in-fy26-research-awards-amid-shifting-funding-landscape 2026-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-secures-nearly-1-8-billion-in-fy26-research-awards-amid-shifting-funding-landscape 2026-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd27-cd39-car-t-cell-count-predicts-response-at-low-doses-study-finds 2026-07-29T23:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd27-cd39-car-t-cell-count-predicts-response-at-low-doses-study-finds 2026-07-29T23:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/rpg-life-sciences-carves-out-api-business-secures-243-crore-pe-backing-to-build-integrated-pharma-platform 2026-07-29T23:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rpg-life-sciences-carves-out-api-business-secures-243-crore-pe-backing-to-build-integrated-pharma-platform 2026-07-29T23:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-choice-awards-2026-announced-at-adlm-thermo-fisher-mindray-siemens-healthineers-and-danaher-among-winners 2026-07-29T22:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-choice-awards-2026-announced-at-adlm-thermo-fisher-mindray-siemens-healthineers-and-danaher-among-winners 2026-07-29T22:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/par-health-launches-sugammadex-prefilled-syringe-to-streamline-neuromuscular-blockade-reversal-in-hospitals 2026-07-29T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/par-health-launches-sugammadex-prefilled-syringe-to-streamline-neuromuscular-blockade-reversal-in-hospitals 2026-07-29T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-turn-to-onlyfans-and-cryptocurrency-to-rescue-60-year-marmot-study-after-federal-funding-cuts 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-turn-to-onlyfans-and-cryptocurrency-to-rescue-60-year-marmot-study-after-federal-funding-cuts 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/rose-hill-life-sciences-names-bryan-smith-scientific-advisor-as-psilocybin-pipeline-advances 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rose-hill-life-sciences-names-bryan-smith-scientific-advisor-as-psilocybin-pipeline-advances 2026-07-29T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/igf2bp3-trnau1ap-pathway-identified-as-promising-therapeutic-target-in-glioblastoma 2026-07-29T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igf2bp3-trnau1ap-pathway-identified-as-promising-therapeutic-target-in-glioblastoma 2026-07-29T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-university-of-vienna-partner-to-target-undruggable-proteins-with-ai-driven-drug-discovery 2026-07-29T21:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elix-and-university-of-vienna-partner-to-target-undruggable-proteins-with-ai-driven-drug-discovery 2026-07-29T21:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-students-urged-to-bridge-research-and-entrepreneurship-at-osmania-university 2026-07-29T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-students-urged-to-bridge-research-and-entrepreneurship-at-osmania-university 2026-07-29T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/programmable-dna-enables-rational-design-of-protein-crystals-overturning-decades-old-assumption 2026-07-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/programmable-dna-enables-rational-design-of-protein-crystals-overturning-decades-old-assumption 2026-07-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-plans-to-end-medicare-part-d-subsidies-potentially-raising-drug-costs-for-millions-of-seniors 2026-07-29T20:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-plans-to-end-medicare-part-d-subsidies-potentially-raising-drug-costs-for-millions-of-seniors 2026-07-29T20:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-long-covid-is-real-landmark-pecos-study-maps-lasting-effects-on-children 2026-07-29T19:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-long-covid-is-real-landmark-pecos-study-maps-lasting-effects-on-children 2026-07-29T19:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-signs-loi-with-vilnius-university-hospital-for-flt3-directed-car-t-therapy-in-aml-mds 2026-07-29T19:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemogenyx-signs-loi-with-vilnius-university-hospital-for-flt3-directed-car-t-therapy-in-aml-mds 2026-07-29T19:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-teleflex-s-ezplaztm-freeze-dried-plasma-transforming-emergency-transfusion-care 2026-07-29T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-teleflex-s-ezplaztm-freeze-dried-plasma-transforming-emergency-transfusion-care 2026-07-29T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/hidden-army-of-tissue-resident-memory-t-cells-defends-human-lungs-against-a-broad-range-of-pathogens 2026-07-29T19:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hidden-army-of-tissue-resident-memory-t-cells-defends-human-lungs-against-a-broad-range-of-pathogens 2026-07-29T19:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-issues-government-wide-ban-on-federal-funding-for-dangerous-gain-of-function-research 2026-07-29T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-issues-government-wide-ban-on-federal-funding-for-dangerous-gain-of-function-research 2026-07-29T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/evinova-and-merck-kgaa-forge-multi-year-ai-partnership-to-transform-clinical-development 2026-07-29T19:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evinova-and-merck-kgaa-forge-multi-year-ai-partnership-to-transform-clinical-development 2026-07-29T19:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/nabp-to-develop-national-adverse-event-reporting-clearinghouse-for-compounded-medications 2026-07-29T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nabp-to-develop-national-adverse-event-reporting-clearinghouse-for-compounded-medications 2026-07-29T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/immature-nk-cells-in-donor-cord-blood-can-sabotage-car-nk-cell-therapy-md-anderson-study-reveals 2026-07-29T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immature-nk-cells-in-donor-cord-blood-can-sabotage-car-nk-cell-therapy-md-anderson-study-reveals 2026-07-29T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-architecture-of-cytokine-autoantibodies-and-associated-risk-of-common-diseases 2026-07-29T18:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-architecture-of-cytokine-autoantibodies-and-associated-risk-of-common-diseases 2026-07-29T18:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/raygun-duke-researchers-develop-ai-tool-that-can-shrink-and-supersize-proteins-while-preserving-function 2026-07-29T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raygun-duke-researchers-develop-ai-tool-that-can-shrink-and-supersize-proteins-while-preserving-function 2026-07-29T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/insidetracker-unveils-source-agnostic-blood-data-connector-across-nearly-120-biomarkers 2026-07-29T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insidetracker-unveils-source-agnostic-blood-data-connector-across-nearly-120-biomarkers 2026-07-29T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/bicara-therapeutics-strengthens-board-with-appointments-of-jeremy-bender-and-christy-oliger-as-company-advances-ficerafusp-alfa-toward-commercialization 2026-07-29T17:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicara-therapeutics-strengthens-board-with-appointments-of-jeremy-bender-and-christy-oliger-as-company-advances-ficerafusp-alfa-toward-commercialization 2026-07-29T17:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-live-cell-imaging-and-cytometry-workflow-standardizes-cerebral-organoid-differentiation-for-drug-discovery 2026-07-29T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-live-cell-imaging-and-cytometry-workflow-standardizes-cerebral-organoid-differentiation-for-drug-discovery 2026-07-29T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/epo-boards-of-appeal-revokes-bms-opdivo-patent-clearing-path-for-nivolumab-biosimilars 2026-07-29T16:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epo-boards-of-appeal-revokes-bms-opdivo-patent-clearing-path-for-nivolumab-biosimilars 2026-07-29T16:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-receives-health-canada-approval-for-yesintek-ustekinumab-autoinjector-pen 2026-07-29T16:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-receives-health-canada-approval-for-yesintek-ustekinumab-autoinjector-pen 2026-07-29T16:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/national-scabies-control-program-using-ivermectin-mda-drastically-reduces-disease-prevalence-in-pacific-nations 2026-07-29T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-scabies-control-program-using-ivermectin-mda-drastically-reduces-disease-prevalence-in-pacific-nations 2026-07-29T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/humigent-raises-series-a-to-build-ai-intelligence-layer-for-life-sciences 2026-07-29T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humigent-raises-series-a-to-build-ai-intelligence-layer-for-life-sciences 2026-07-29T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/pk-med-strengthens-governance-with-gene-therapy-pioneers-ahead-of-phase-2-gout-trial 2026-07-29T16:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pk-med-strengthens-governance-with-gene-therapy-pioneers-ahead-of-phase-2-gout-trial 2026-07-29T16:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/enzyme-based-platform-yields-novel-polyene-antifungals-with-superior-potency-and-reduced-toxicity 2026-07-29T16:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzyme-based-platform-yields-novel-polyene-antifungals-with-superior-potency-and-reduced-toxicity 2026-07-29T16:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/angelman-syndrome-foundation-and-citizen-health-partner-to-bring-ai-advocate-ari-to-angelman-families 2026-07-29T16:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angelman-syndrome-foundation-and-citizen-health-partner-to-bring-ai-advocate-ari-to-angelman-families 2026-07-29T16:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-and-sequencing-essential-in-metastatic-triple-negative-breast-cancer-expert-urges 2026-07-29T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-and-sequencing-essential-in-metastatic-triple-negative-breast-cancer-expert-urges 2026-07-29T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-therapy-market-poised-for-rapid-expansion-as-precision-immunotherapy-advances 2026-07-29T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytic-virus-therapy-market-poised-for-rapid-expansion-as-precision-immunotherapy-advances 2026-07-29T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-sven-k-weber-appointed-ceo-of-brain-biotech-ag-succeeding-adriaan-moelker 2026-07-29T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-sven-k-weber-appointed-ceo-of-brain-biotech-ag-succeeding-adriaan-moelker 2026-07-29T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-acquires-vidya-therapeutics-secures-200-million-financing-to-advance-next-generation-btk-inhibitor-vt-7208 2026-07-29T16:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/processa-pharmaceuticals-acquires-vidya-therapeutics-secures-200-million-financing-to-advance-next-generation-btk-inhibitor-vt-7208 2026-07-29T16:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/deepmind-dismantles-alphafold-team-as-nobel-laureates-exit-for-rivals-shifting-ai-drug-discovery-landscape 2026-07-29T16:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepmind-dismantles-alphafold-team-as-nobel-laureates-exit-for-rivals-shifting-ai-drug-discovery-landscape 2026-07-29T16:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-beats-q2-estimates-as-rare-disease-portfolio-and-leqembi-drive-growth-raises-2026-revenue-outlook 2026-07-29T16:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-beats-q2-estimates-as-rare-disease-portfolio-and-leqembi-drive-growth-raises-2026-revenue-outlook 2026-07-29T16:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/ems-and-bd-launch-semaglutide-therapy-in-brazil-expanding-glp-1-access-with-advanced-injection-pen-platform 2026-07-29T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ems-and-bd-launch-semaglutide-therapy-in-brazil-expanding-glp-1-access-with-advanced-injection-pen-platform 2026-07-29T16:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/flinders-university-secures-9m-nhmrc-funding-for-three-centres-of-research-excellence 2026-07-29T16:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flinders-university-secures-9m-nhmrc-funding-for-three-centres-of-research-excellence 2026-07-29T16:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/high-thc-medicinal-cannabis-prescribing-in-australia-far-outpaces-clinical-evidence-review-finds 2026-07-29T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-thc-medicinal-cannabis-prescribing-in-australia-far-outpaces-clinical-evidence-review-finds 2026-07-29T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-expanded-repatha-indication-for-primary-prevention-of-first-heart-attack-and-stroke 2026-07-29T15:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-expanded-repatha-indication-for-primary-prevention-of-first-heart-attack-and-stroke 2026-07-29T15:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-therapeutics-closes-31m-financing-to-advance-sarna-pipeline-and-extrahepatic-delivery-platforms 2026-07-29T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-therapeutics-closes-31m-financing-to-advance-sarna-pipeline-and-extrahepatic-delivery-platforms 2026-07-29T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/vivid-dx-raises-15m-seed-funding-to-advance-ai-powered-rapid-diagnostics-for-drug-resistant-infections 2026-07-29T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivid-dx-raises-15m-seed-funding-to-advance-ai-powered-rapid-diagnostics-for-drug-resistant-infections 2026-07-29T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/platinum-chemotherapy-leaves-lasting-genomic-scars-in-children-s-livers-study-finds 2026-07-29T15:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/platinum-chemotherapy-leaves-lasting-genomic-scars-in-children-s-livers-study-finds 2026-07-29T15:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-28-2m-to-penn-state-ctsi-to-expand-rural-clinical-trial-access-and-health-research 2026-07-29T14:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-28-2m-to-penn-state-ctsi-to-expand-rural-clinical-trial-access-and-health-research 2026-07-29T14:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/tasrif-pharmaceutical-secures-second-u-s-patent-for-cd155-targeting-antibodies-as-anti-tigit-field-contracts 2026-07-29T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tasrif-pharmaceutical-secures-second-u-s-patent-for-cd155-targeting-antibodies-as-anti-tigit-field-contracts 2026-07-29T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/red-light-holland-rebrands-to-rhelion-life-sciences-advances-naturally-derived-psilocybin-drug-pex010-toward-phase-ii-clinical-development 2026-07-29T14:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/red-light-holland-rebrands-to-rhelion-life-sciences-advances-naturally-derived-psilocybin-drug-pex010-toward-phase-ii-clinical-development 2026-07-29T14:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/fnih-launches-landmark-map-d-study-to-redefine-depression-diagnosis-and-treatment-through-precision-medicine 2026-07-29T14:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fnih-launches-landmark-map-d-study-to-redefine-depression-diagnosis-and-treatment-through-precision-medicine 2026-07-29T14:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/cyrano-therapeutics-cyr-064-phase-2-flavor-trial-results-to-be-featured-at-american-rhinologic-society-annual-meeting 2026-07-29T14:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyrano-therapeutics-cyr-064-phase-2-flavor-trial-results-to-be-featured-at-american-rhinologic-society-annual-meeting 2026-07-29T14:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-secures-30-million-barda-tranche-to-advance-fosmanogepix-phase-iii-program-for-invasive-fungal-infections 2026-07-29T13:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-secures-30-million-barda-tranche-to-advance-fosmanogepix-phase-iii-program-for-invasive-fungal-infections 2026-07-29T13:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-makes-strategic-investment-in-trace-biosciences-to-advance-nerve-specific-intraoperative-imaging-technology 2026-07-29T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axogen-makes-strategic-investment-in-trace-biosciences-to-advance-nerve-specific-intraoperative-imaging-technology 2026-07-29T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/shape-therapeutics-secures-mjff-grant-to-advance-shp-201-a-one-time-rna-editing-gene-therapy-for-parkinson-s-disease 2026-07-29T11:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shape-therapeutics-secures-mjff-grant-to-advance-shp-201-a-one-time-rna-editing-gene-therapy-for-parkinson-s-disease 2026-07-29T11:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-c2n-diagnostics-precivityad2-blood-test-for-alzheimer-s-in-adults-as-young-as-40 2026-07-29T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-c2n-diagnostics-precivityad2-blood-test-for-alzheimer-s-in-adults-as-young-as-40 2026-07-29T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-semaglutide-reduces-heavy-drinking-in-alcohol-use-disorder-cu-anschutz-clinical-trial-results 2026-07-29T09:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-semaglutide-reduces-heavy-drinking-in-alcohol-use-disorder-cu-anschutz-clinical-trial-results 2026-07-29T09:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/exploiting-rna-polymerase-vulnerabilities-a-new-strategy-against-drug-resistant-tuberculosis 2026-07-29T08:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exploiting-rna-polymerase-vulnerabilities-a-new-strategy-against-drug-resistant-tuberculosis 2026-07-29T08:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-strong-link-between-cutaneous-melanoma-and-uveal-melanoma-risk 2026-07-29T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-strong-link-between-cutaneous-melanoma-and-uveal-melanoma-risk 2026-07-29T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/unsw-researchers-awarded-61-million-in-nhmrc-investigator-grants-to-advance-autoimmune-oncology-and-genomics-research 2026-07-29T07:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unsw-researchers-awarded-61-million-in-nhmrc-investigator-grants-to-advance-autoimmune-oncology-and-genomics-research 2026-07-29T07:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/yale-school-of-medicine-launches-online-master-of-health-science-in-medical-ai-to-bridge-the-clinical-technical-divide 2026-07-29T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-school-of-medicine-launches-online-master-of-health-science-in-medical-ai-to-bridge-the-clinical-technical-divide 2026-07-29T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/csl-to-begin-clinical-trials-for-horizon-2-immunoglobulin-manufacturing-process-following-fda-and-ema-discussions 2026-07-29T04:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-to-begin-clinical-trials-for-horizon-2-immunoglobulin-manufacturing-process-following-fda-and-ema-discussions 2026-07-29T04:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/personalised-medicine-and-parp-inhibitors-transform-stage-iv-breast-cancer-outcomes-a-decade-of-progress-in-northern-ireland 2026-07-29T01:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalised-medicine-and-parp-inhibitors-transform-stage-iv-breast-cancer-outcomes-a-decade-of-progress-in-northern-ireland 2026-07-29T01:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/spring-daylight-saving-time-linked-to-30-increased-risk-of-retinal-vascular-diseases-large-scale-study-finds 2026-07-29T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spring-daylight-saving-time-linked-to-30-increased-risk-of-retinal-vascular-diseases-large-scale-study-finds 2026-07-29T00:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/unr-med-and-renown-health-build-nevada-s-first-integrated-academic-health-system-expanding-clinical-trials-and-research-infrastructure 2026-07-28T22:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unr-med-and-renown-health-build-nevada-s-first-integrated-academic-health-system-expanding-clinical-trials-and-research-infrastructure 2026-07-28T22:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/us-hiv-funding-cuts-slashed-new-patient-enrollment-59-across-east-africa-within-weeks 2026-07-28T22:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-hiv-funding-cuts-slashed-new-patient-enrollment-59-across-east-africa-within-weeks 2026-07-28T22:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/uw-health-launches-proton-therapy-program-for-cancer-patients-through-clinical-trial 2026-07-28T22:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uw-health-launches-proton-therapy-program-for-cancer-patients-through-clinical-trial 2026-07-28T22:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aacr-oncology-educational-fellowship-opens-applications-for-2026-2027-cohort 2026-07-28T22:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aacr-oncology-educational-fellowship-opens-applications-for-2026-2027-cohort 2026-07-28T22:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/plant-proteins-that-imitate-fiber-reprogram-gut-microbes-to-favor-healthy-metabolites 2026-07-28T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plant-proteins-that-imitate-fiber-reprogram-gut-microbes-to-favor-healthy-metabolites 2026-07-28T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/centene-swings-to-1-1-billion-q2-profit-as-medical-costs-stabilize-and-aca-business-rebounds 2026-07-28T20:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centene-swings-to-1-1-billion-q2-profit-as-medical-costs-stabilize-and-aca-business-rebounds 2026-07-28T20:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/mirae-launches-with-5-4m-to-bring-ai-driven-continuous-care-to-autoimmune-disease 2026-07-28T19:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirae-launches-with-5-4m-to-bring-ai-driven-continuous-care-to-autoimmune-disease 2026-07-28T19:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/belize-achieves-full-membership-in-who-programme-for-international-drug-monitoring 2026-07-28T19:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belize-achieves-full-membership-in-who-programme-for-international-drug-monitoring 2026-07-28T19:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/first-mrna-vaccine-for-elephants-shows-evidence-of-protection-against-deadly-eehv 2026-07-28T19:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-mrna-vaccine-for-elephants-shows-evidence-of-protection-against-deadly-eehv 2026-07-28T19:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-makeup-may-determine-whether-low-carb-diets-raise-ldl-cholesterol 2026-07-28T18:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-makeup-may-determine-whether-low-carb-diets-raise-ldl-cholesterol 2026-07-28T18:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/curebound-strengthens-leadership-with-three-key-executive-hires-to-accelerate-cancer-research 2026-07-28T18:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curebound-strengthens-leadership-with-three-key-executive-hires-to-accelerate-cancer-research 2026-07-28T18:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lists-patent-for-hemiclor-12-5-mg-chlorthalidone-in-orange-book-securing-formulation-protection-through-2045 2026-07-28T17:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lists-patent-for-hemiclor-12-5-mg-chlorthalidone-in-orange-book-securing-formulation-protection-through-2045 2026-07-28T17:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-yeast-factory-boosts-cancer-drug-production-1000-times 2026-07-28T17:11:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-yeast-factory-boosts-cancer-drug-production-1000-times 2026-07-28T17:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/rosie-o-donnell-details-slow-titration-mounjaro-regimen-reports-zero-side-effects-over-three-years 2026-07-28T17:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rosie-o-donnell-details-slow-titration-mounjaro-regimen-reports-zero-side-effects-over-three-years 2026-07-28T17:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-across-drug-discovery 2026-07-28T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-across-drug-discovery 2026-07-28T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-secures-multi-hundred-million-dollar-commercial-manufacturing-agreement-for-new-yokohama-site-ahead-of-2027-opening 2026-07-28T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-secures-multi-hundred-million-dollar-commercial-manufacturing-agreement-for-new-yokohama-site-ahead-of-2027-opening 2026-07-28T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/ich-e6-r3-reshapes-data-governance-accountability-across-sponsors-and-sites 2026-07-28T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ich-e6-r3-reshapes-data-governance-accountability-across-sponsors-and-sites 2026-07-28T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/human-specific-srgap2-gene-slows-microglia-maturation-shedding-light-on-human-cognitive-evolution 2026-07-28T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-specific-srgap2-gene-slows-microglia-maturation-shedding-light-on-human-cognitive-evolution 2026-07-28T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/industrial-chicken-farming-drives-100-fold-increase-in-campylobacter-spread-oxford-study-finds 2026-07-28T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/industrial-chicken-farming-drives-100-fold-increase-in-campylobacter-spread-oxford-study-finds 2026-07-28T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-hexavalent-gbs-vaccine-clears-phase-1-2-but-the-real-test-lies-in-defining-a-correlate-of-protection 2026-07-28T16:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-hexavalent-gbs-vaccine-clears-phase-1-2-but-the-real-test-lies-in-defining-a-correlate-of-protection 2026-07-28T16:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/treeline-biosciences-registers-first-in-human-phase-i-trial-of-bcl-xl-degrader-tln-499-combined-with-venetoclax-in-solid-tumors 2026-07-28T16:12:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treeline-biosciences-registers-first-in-human-phase-i-trial-of-bcl-xl-degrader-tln-499-combined-with-venetoclax-in-solid-tumors 2026-07-28T16:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-costs-top-121000-annually-in-end-of-life-phase-acs-study-reveals-stark-stage-based-disparities 2026-07-28T16:12:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-costs-top-121000-annually-in-end-of-life-phase-acs-study-reveals-stark-stage-based-disparities 2026-07-28T16:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/brainstorm-appoints-former-fda-associate-commissioner-peter-pitts-as-executive-chairman-to-lead-nurown-phase-3b-als-strategy 2026-07-28T16:12:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainstorm-appoints-former-fda-associate-commissioner-peter-pitts-as-executive-chairman-to-lead-nurown-phase-3b-als-strategy 2026-07-28T16:12:05+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-quest-fund-backs-venetoclax-tarlatamab-combination-study-in-small-cell-lung-cancer 2026-07-28T16:12:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-quest-fund-backs-venetoclax-tarlatamab-combination-study-in-small-cell-lung-cancer 2026-07-28T16:12:05+00:00 hourly 0.9 https://trial.medpath.com/news/amorphical-completes-full-enrollment-in-phase-2-trial-of-amor-1-for-hypoparathyroidism-data-readout-expected-q4-2026 2026-07-28T16:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amorphical-completes-full-enrollment-in-phase-2-trial-of-amor-1-for-hypoparathyroidism-data-readout-expected-q4-2026 2026-07-28T16:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/epigenomics-market-poised-to-reach-69-6-billion-by-2034-on-15-2-cagr-driven-by-oncology-and-precision-medicine 2026-07-28T16:11:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenomics-market-poised-to-reach-69-6-billion-by-2034-on-15-2-cagr-driven-by-oncology-and-precision-medicine 2026-07-28T16:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/uniquity-bio-appoints-jason-moore-as-svp-of-regulatory-quality-ahead-of-pivotal-solrikitug-data-readouts 2026-07-28T16:11:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniquity-bio-appoints-jason-moore-as-svp-of-regulatory-quality-ahead-of-pivotal-solrikitug-data-readouts 2026-07-28T16:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/firefly-neuroscience-and-next-health-launch-precision-cognitive-health-platform-following-fda-advisory-committee-recommendation-on-neuroprotective-peptides 2026-07-28T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/firefly-neuroscience-and-next-health-launch-precision-cognitive-health-platform-following-fda-advisory-committee-recommendation-on-neuroprotective-peptides 2026-07-28T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/nord-expands-rare-disease-centers-of-excellence-network-with-three-new-institutions 2026-07-28T16:11:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nord-expands-rare-disease-centers-of-excellence-network-with-three-new-institutions 2026-07-28T16:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-vitamin-b3-offers-new-hope-for-children-with-rare-naxd-deficiency 2026-07-28T16:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-vitamin-b3-offers-new-hope-for-children-with-rare-naxd-deficiency 2026-07-28T16:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/state-drug-price-caps-fail-to-lower-patient-costs-and-threaten-rare-disease-access-new-raap-study-finds 2026-07-28T15:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/state-drug-price-caps-fail-to-lower-patient-costs-and-threaten-rare-disease-access-new-raap-study-finds 2026-07-28T15:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-gwas-of-2-5-million-individuals-reveals-26-genetic-risk-loci-for-fibromyalgia-implicating-nervous-system-origins 2026-07-28T15:11:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-gwas-of-2-5-million-individuals-reveals-26-genetic-risk-loci-for-fibromyalgia-implicating-nervous-system-origins 2026-07-28T15:11:14+00:00 hourly 0.9 https://trial.medpath.com/news/philogen-resubmits-nidlegy-marketing-application-to-ema-with-extended-phase-iii-melanoma-data 2026-07-28T15:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philogen-resubmits-nidlegy-marketing-application-to-ema-with-extended-phase-iii-melanoma-data 2026-07-28T15:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/malaysia-registers-26-orphan-medicines-since-2020-as-rare-disease-list-reaches-529-conditions 2026-07-28T15:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysia-registers-26-orphan-medicines-since-2020-as-rare-disease-list-reaches-529-conditions 2026-07-28T15:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/sheba-medical-center-becomes-first-hospital-outside-the-u-s-to-adopt-openai-s-healthcare-ai-models 2026-07-28T15:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sheba-medical-center-becomes-first-hospital-outside-the-u-s-to-adopt-openai-s-healthcare-ai-models 2026-07-28T15:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/core-biomedicine-secures-21-million-series-a-and-eisai-licensing-deal-to-advance-lineage-based-precision-oncology-pipeline 2026-07-28T14:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/core-biomedicine-secures-21-million-series-a-and-eisai-licensing-deal-to-advance-lineage-based-precision-oncology-pipeline 2026-07-28T14:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-secures-fda-approval-for-first-u-s-manufactured-generic-advair-diskus-across-all-three-strengths 2026-07-28T14:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-secures-fda-approval-for-first-u-s-manufactured-generic-advair-diskus-across-all-three-strengths 2026-07-28T14:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/promatix-biosciences-awarded-innovate-uk-grant-to-advance-first-in-class-egfr-x-epha2-cis-bispecific-adc 2026-07-28T14:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promatix-biosciences-awarded-innovate-uk-grant-to-advance-first-in-class-egfr-x-epha2-cis-bispecific-adc 2026-07-28T14:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/dasher-neuroscience-completes-patient-enrollment-in-phase-2-trial-of-ya-101-for-multiple-system-atrophy 2026-07-28T14:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dasher-neuroscience-completes-patient-enrollment-in-phase-2-trial-of-ya-101-for-multiple-system-atrophy 2026-07-28T14:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-develops-helical-polypeptide-nanoparticle-that-forces-cancer-cells-to-signal-their-own-destruction 2026-07-28T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaist-develops-helical-polypeptide-nanoparticle-that-forces-cancer-cells-to-signal-their-own-destruction 2026-07-28T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/stimulate-icp-largest-long-covid-trial-finds-specialist-care-reduces-fatigue-but-multi-organ-mri-adds-no-benefit 2026-07-28T11:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stimulate-icp-largest-long-covid-trial-finds-specialist-care-reduces-fatigue-but-multi-organ-mri-adds-no-benefit 2026-07-28T11:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/gate-2027-iit-madras-revises-biotechnology-syllabus-expands-two-paper-combinations 2026-07-28T10:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gate-2027-iit-madras-revises-biotechnology-syllabus-expands-two-paper-combinations 2026-07-28T10:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/who-calls-for-urgent-action-on-hepatitis-as-hepatitis-d-remains-an-overlooked-threat 2026-07-28T09:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-calls-for-urgent-action-on-hepatitis-as-hepatitis-d-remains-an-overlooked-threat 2026-07-28T09:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-silent-rise-in-chronic-respiratory-diseases-spurs-ai-driven-remote-monitoring-innovation 2026-07-28T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-silent-rise-in-chronic-respiratory-diseases-spurs-ai-driven-remote-monitoring-innovation 2026-07-28T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lepu-biopharma-and-astrazeneca-announce-positive-phase-iii-results-for-cmg901-in-advanced-gastric-cancer 2026-07-28T07:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lepu-biopharma-and-astrazeneca-announce-positive-phase-iii-results-for-cmg901-in-advanced-gastric-cancer 2026-07-28T07:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-biopsies-reveal-how-sglt2-inhibitor-dapagliflozin-protects-against-early-diabetic-kidney-disease-in-youth-with-type-1-diabetes 2026-07-28T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kidney-biopsies-reveal-how-sglt2-inhibitor-dapagliflozin-protects-against-early-diabetic-kidney-disease-in-youth-with-type-1-diabetes 2026-07-28T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/milvexian-fails-to-reduce-cardiovascular-events-after-acute-coronary-syndrome-in-librexia-acs-trial 2026-07-28T04:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milvexian-fails-to-reduce-cardiovascular-events-after-acute-coronary-syndrome-in-librexia-acs-trial 2026-07-28T04:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/in-person-navigation-outperforms-signposting-in-social-prescribing-trial-with-key-equity-gains-for-language-minorities 2026-07-28T02:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-person-navigation-outperforms-signposting-in-social-prescribing-trial-with-key-equity-gains-for-language-minorities 2026-07-28T02:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-secures-fda-510-k-clearance-for-monarch-quest-3-bronchoscopy-system 2026-07-28T00:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-secures-fda-510-k-clearance-for-monarch-quest-3-bronchoscopy-system 2026-07-28T00:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/teen-cannabis-use-linked-to-slower-cognitive-growth-thc-identified-as-key-driver 2026-07-28T00:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teen-cannabis-use-linked-to-slower-cognitive-growth-thc-identified-as-key-driver 2026-07-28T00:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-validated-scale-to-measure-generative-ai-addiction-in-undergraduate-students 2026-07-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-validated-scale-to-measure-generative-ai-addiction-in-undergraduate-students 2026-07-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antioxidant-therapy-bypasses-genetic-defect-in-22q11-2-deletion-syndrome-via-alternative-gene-networks 2026-07-27T23:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antioxidant-therapy-bypasses-genetic-defect-in-22q11-2-deletion-syndrome-via-alternative-gene-networks 2026-07-27T23:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/report-calls-on-tiktok-to-shut-down-unregulated-glp-1-gray-market 2026-07-27T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/report-calls-on-tiktok-to-shut-down-unregulated-glp-1-gray-market 2026-07-27T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-johnson-johnson-s-ottava-robotic-assisted-surgery-system-marking-entry-into-surgical-robotics 2026-07-27T23:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-johnson-johnson-s-ottava-robotic-assisted-surgery-system-marking-entry-into-surgical-robotics 2026-07-27T23:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/ai-generated-doctors-on-tiktok-pose-huge-danger-to-public-safety-experts-warn 2026-07-27T23:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-generated-doctors-on-tiktok-pose-huge-danger-to-public-safety-experts-warn 2026-07-27T23:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/kansas-city-man-becomes-youngest-person-potentially-cured-of-hiv-after-stem-cell-transplant 2026-07-27T22:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kansas-city-man-becomes-youngest-person-potentially-cured-of-hiv-after-stem-cell-transplant 2026-07-27T22:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-three-guidances-to-broaden-cancer-clinical-trial-eligibility 2026-07-27T22:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-finalizes-three-guidances-to-broaden-cancer-clinical-trial-eligibility 2026-07-27T22:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/saskatchewan-establishes-provincial-advisory-committee-to-tackle-primary-care-access-considers-patient-attachment-registry 2026-07-27T22:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saskatchewan-establishes-provincial-advisory-committee-to-tackle-primary-care-access-considers-patient-attachment-registry 2026-07-27T22:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-2-4-million-r01-grant-to-investigate-how-maternal-viral-infections-reprogram-fetal-immune-development-in-a-sex-specific-manner 2026-07-27T22:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-2-4-million-r01-grant-to-investigate-how-maternal-viral-infections-reprogram-fetal-immune-development-in-a-sex-specific-manner 2026-07-27T22:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/elevar-therapeutics-to-present-three-abstracts-at-esmo-2026-including-phase-2-thrive-trial-of-rivoceranib-in-thymic-tumors 2026-07-27T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevar-therapeutics-to-present-three-abstracts-at-esmo-2026-including-phase-2-thrive-trial-of-rivoceranib-in-thymic-tumors 2026-07-27T21:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/sarcomatrix-advances-s-969-toward-first-in-human-dosing-with-sarcovista-modeling-and-expanded-cmc-package 2026-07-27T21:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarcomatrix-advances-s-969-toward-first-in-human-dosing-with-sarcovista-modeling-and-expanded-cmc-package 2026-07-27T21:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/asymchem-s-carbapenem-api-facility-passes-first-usfda-pre-approval-inspection 2026-07-27T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asymchem-s-carbapenem-api-facility-passes-first-usfda-pre-approval-inspection 2026-07-27T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/apa-2026-real-world-gad-treatment-gaps-and-preclinical-safety-data-for-5-ht2a-agonist-dt120 2026-07-27T20:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apa-2026-real-world-gad-treatment-gaps-and-preclinical-safety-data-for-5-ht2a-agonist-dt120 2026-07-27T20:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-navajo-medically-tailored-meals-reduced-heart-failure-hospitalizations-by-more-than-half-in-landmark-randomized-trial 2026-07-27T20:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traditional-navajo-medically-tailored-meals-reduced-heart-failure-hospitalizations-by-more-than-half-in-landmark-randomized-trial 2026-07-27T20:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-nanoparticles-deliver-dual-action-mrna-and-drug-therapy-against-oral-cancer 2026-07-27T19:11:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipid-nanoparticles-deliver-dual-action-mrna-and-drug-therapy-against-oral-cancer 2026-07-27T19:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-classifies-nationwide-recall-of-levothyroxine-sodium-tablets-as-class-ii-due-to-subpotency 2026-07-27T19:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-classifies-nationwide-recall-of-levothyroxine-sodium-tablets-as-class-ii-due-to-subpotency 2026-07-27T19:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/siemens-healthineers-and-cleveland-clinic-launch-10-year-strategic-alliance-to-advance-diagnostic-imaging-theranostics-and-clinical-innovation 2026-07-27T18:24:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siemens-healthineers-and-cleveland-clinic-launch-10-year-strategic-alliance-to-advance-diagnostic-imaging-theranostics-and-clinical-innovation 2026-07-27T18:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-injectables-gene-editing-and-bnabs-the-non-vaccine-arsenal-closing-the-gap-in-hiv-prevention 2026-07-27T18:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-injectables-gene-editing-and-bnabs-the-non-vaccine-arsenal-closing-the-gap-in-hiv-prevention 2026-07-27T18:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-researchers-awarded-3-3-million-nih-grant-to-study-cultural-differences-in-subjective-cognitive-decline 2026-07-27T18:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-researchers-awarded-3-3-million-nih-grant-to-study-cultural-differences-in-subjective-cognitive-decline 2026-07-27T18:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/3d-genome-mapping-reveals-a-hidden-layer-of-alzheimer-s-pathology 2026-07-27T18:24:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-genome-mapping-reveals-a-hidden-layer-of-alzheimer-s-pathology 2026-07-27T18:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/uva-health-receives-6-5-million-nih-grant-to-develop-salt-mri-for-lymphatic-disease-diagnosis 2026-07-27T18:23:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-health-receives-6-5-million-nih-grant-to-develop-salt-mri-for-lymphatic-disease-diagnosis 2026-07-27T18:23:11+00:00 hourly 0.9 https://trial.medpath.com/news/aman-clinics-partners-with-cenegenics-to-launch-precision-medicine-and-longevity-program-in-qatar 2026-07-27T18:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aman-clinics-partners-with-cenegenics-to-launch-precision-medicine-and-longevity-program-in-qatar 2026-07-27T18:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/lapix-therapeutics-appoints-nimbus-ceo-abbas-kazimi-to-board-as-oral-tim-3-tim-4-agonist-advances-through-phase-1b-trials 2026-07-27T18:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lapix-therapeutics-appoints-nimbus-ceo-abbas-kazimi-to-board-as-oral-tim-3-tim-4-agonist-advances-through-phase-1b-trials 2026-07-27T18:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/honeynaps-registers-as-cro-accelerating-ai-powered-sleep-data-analytics-for-global-clinical-trials 2026-07-27T18:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/honeynaps-registers-as-cro-accelerating-ai-powered-sleep-data-analytics-for-global-clinical-trials 2026-07-27T18:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/clinton-foundation-launches-policy-institute-to-advance-nonpartisan-health-solutions-at-the-state-level 2026-07-27T18:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinton-foundation-launches-policy-institute-to-advance-nonpartisan-health-solutions-at-the-state-level 2026-07-27T18:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-faces-growing-exodus-of-biomedical-scientists-as-funding-uncertainty-and-visa-costs-erode-research-talent 2026-07-27T18:22:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-faces-growing-exodus-of-biomedical-scientists-as-funding-uncertainty-and-visa-costs-erode-research-talent 2026-07-27T18:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-turn-covid-19-immune-memory-into-a-powerful-new-ally-against-cancer 2026-07-27T18:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-turn-covid-19-immune-memory-into-a-powerful-new-ally-against-cancer 2026-07-27T18:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/isoprene-pharmaceuticals-secures-1-02m-nci-grant-to-advance-dual-targeting-molecular-glue-degrader-for-castration-resistant-prostate-cancer 2026-07-27T18:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isoprene-pharmaceuticals-secures-1-02m-nci-grant-to-advance-dual-targeting-molecular-glue-degrader-for-castration-resistant-prostate-cancer 2026-07-27T18:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/spero-therapeutics-appoints-dr-debra-jeske-zack-as-cmo-to-lead-phase-2-ready-anti-cd40l-antibody-sp001 2026-07-27T18:20:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spero-therapeutics-appoints-dr-debra-jeske-zack-as-cmo-to-lead-phase-2-ready-anti-cd40l-antibody-sp001 2026-07-27T18:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/entera-bio-secures-275-million-to-fund-phase-iii-trial-of-first-oral-osteoanabolic-tablet-for-osteoporosis 2026-07-27T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entera-bio-secures-275-million-to-fund-phase-iii-trial-of-first-oral-osteoanabolic-tablet-for-osteoporosis 2026-07-27T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/lgmd-advocates-from-20-states-press-congress-as-first-subtype-treatment-nears 2026-07-27T18:16:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lgmd-advocates-from-20-states-press-congress-as-first-subtype-treatment-nears 2026-07-27T18:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/revagenix-doses-first-participant-in-phase-1-trial-of-rev-56-a-first-in-class-inhaled-anti-pseudomonal-therapy-for-non-cf-bronchiectasis 2026-07-27T18:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revagenix-doses-first-participant-in-phase-1-trial-of-rev-56-a-first-in-class-inhaled-anti-pseudomonal-therapy-for-non-cf-bronchiectasis 2026-07-27T18:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/cognizant-expands-20-year-partnership-with-novartis-for-ai-enabled-global-it-operations-transformation 2026-07-27T18:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognizant-expands-20-year-partnership-with-novartis-for-ai-enabled-global-it-operations-transformation 2026-07-27T18:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/leerink-partners-report-names-carterra-a-core-enabler-of-the-7b-lab-in-the-loop-antibody-discovery-market 2026-07-27T15:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leerink-partners-report-names-carterra-a-core-enabler-of-the-7b-lab-in-the-loop-antibody-discovery-market 2026-07-27T15:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-deploys-schrodinger-s-bunsen-ai-co-scientist-at-scale-to-accelerate-drug-discovery 2026-07-27T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-deploys-schrodinger-s-bunsen-ai-co-scientist-at-scale-to-accelerate-drug-discovery 2026-07-27T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/difgen-pharmaceuticals-receives-fda-clearance-for-single-injection-breast-cancer-therapy-dfgn-101 2026-07-27T15:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/difgen-pharmaceuticals-receives-fda-clearance-for-single-injection-breast-cancer-therapy-dfgn-101 2026-07-27T15:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/mana-bio-appoints-gene-therapy-pioneer-laura-sepp-lorenzino-to-scientific-advisory-board 2026-07-27T15:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mana-bio-appoints-gene-therapy-pioneer-laura-sepp-lorenzino-to-scientific-advisory-board 2026-07-27T15:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/circular-eccdna-features-offer-new-prognostic-insights-for-early-stage-lung-adenocarcinoma-recurrence 2026-07-27T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-eccdna-features-offer-new-prognostic-insights-for-early-stage-lung-adenocarcinoma-recurrence 2026-07-27T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-s-core-operating-profit-rises-on-strong-hemlibra-exports-and-growing-royalty-stream 2026-07-27T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-s-core-operating-profit-rises-on-strong-hemlibra-exports-and-growing-royalty-stream 2026-07-27T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/lukashenko-proposes-belarus-russia-biotechnology-collaboration-highlighting-bnbc-s-deep-grain-processing-capabilities 2026-07-27T12:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lukashenko-proposes-belarus-russia-biotechnology-collaboration-highlighting-bnbc-s-deep-grain-processing-capabilities 2026-07-27T12:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-voluntary-data-submission-pilot-to-build-regulatory-evidence-for-organ-chips-and-other-new-approach-methodologies 2026-07-27T12:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-launches-voluntary-data-submission-pilot-to-build-regulatory-evidence-for-organ-chips-and-other-new-approach-methodologies 2026-07-27T12:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-oral-psoriasis-drug-fadeucravacitinib-meets-primary-goal-in-phase-iii-trial-regulatory-filing-planned 2026-07-27T12:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-oral-psoriasis-drug-fadeucravacitinib-meets-primary-goal-in-phase-iii-trial-regulatory-filing-planned 2026-07-27T12:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/bms-launches-india-s-first-lag-3-based-dual-immunotherapy-for-metastatic-melanoma 2026-07-27T11:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-launches-india-s-first-lag-3-based-dual-immunotherapy-for-metastatic-melanoma 2026-07-27T11:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/blood-protein-biomarker-panel-predicts-als-symptom-onset-within-two-years 2026-07-27T11:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-protein-biomarker-panel-predicts-als-symptom-onset-within-two-years 2026-07-27T11:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/trace-neuroscience-launches-first-in-human-trials-of-unc13a-targeting-aso-for-als-while-experts-als-platform-demonstrates-rapid-drug-screening-capability 2026-07-27T11:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trace-neuroscience-launches-first-in-human-trials-of-unc13a-targeting-aso-for-als-while-experts-als-platform-demonstrates-rapid-drug-screening-capability 2026-07-27T11:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/itm-launches-lumara-bio-as-dedicated-oncology-division-ahead-of-pdufa-date-for-lead-radiopharmaceutical-177lu-edotreotide 2026-07-27T11:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-launches-lumara-bio-as-dedicated-oncology-division-ahead-of-pdufa-date-for-lead-radiopharmaceutical-177lu-edotreotide 2026-07-27T11:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/verily-nvidia-and-nih-build-first-multimodal-foundation-model-integrating-ehr-and-genomic-data-to-improve-type-2-diabetes-risk-prediction 2026-07-27T11:09:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verily-nvidia-and-nih-build-first-multimodal-foundation-model-integrating-ehr-and-genomic-data-to-improve-type-2-diabetes-risk-prediction 2026-07-27T11:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-trial-diversity-gap-in-parkinson-s-disease-becomes-an-urgent-site-operations-crisis 2026-07-27T10:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-trial-diversity-gap-in-parkinson-s-disease-becomes-an-urgent-site-operations-crisis 2026-07-27T10:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/dong-a-st-posts-record-q2-sales-of-krw-207-8-billion-operating-profit-surges-170 2026-07-27T10:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dong-a-st-posts-record-q2-sales-of-krw-207-8-billion-operating-profit-surges-170 2026-07-27T10:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-patents-subcutaneous-adc-formulation-using-hydiffuze-platform-demonstrating-126-increase-in-systemic-drug-exposure 2026-07-27T09:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-patents-subcutaneous-adc-formulation-using-hydiffuze-platform-demonstrating-126-increase-in-systemic-drug-exposure 2026-07-27T09:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/hofseth-biocare-s-progo-r-bioactive-peptides-show-multi-target-effects-on-healthy-ageing-in-peer-reviewed-clinical-study 2026-07-27T09:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hofseth-biocare-s-progo-r-bioactive-peptides-show-multi-target-effects-on-healthy-ageing-in-peer-reviewed-clinical-study 2026-07-27T09:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/ultomiris-phase-iii-trial-misses-primary-endpoint-in-adults-with-hsct-tma-but-paediatric-data-show-clinically-meaningful-survival-benefit 2026-07-27T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultomiris-phase-iii-trial-misses-primary-endpoint-in-adults-with-hsct-tma-but-paediatric-data-show-clinically-meaningful-survival-benefit 2026-07-27T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/faron-reports-encouraging-first-overall-survival-data-for-bexmarilimab-in-frontline-hr-mds-median-os-not-yet-reached-in-key-subgroups 2026-07-27T08:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-reports-encouraging-first-overall-survival-data-for-bexmarilimab-in-frontline-hr-mds-median-os-not-yet-reached-in-key-subgroups 2026-07-27T08:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-to-present-first-in-human-phase-1-data-for-ai-designed-pan-tead-inhibitor-ism6331-at-esmo-2026 2026-07-27T08:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-to-present-first-in-human-phase-1-data-for-ai-designed-pan-tead-inhibitor-ism6331-at-esmo-2026 2026-07-27T08:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/samchundang-pharm-reaches-global-settlement-in-eylea-biosimilar-patent-dispute-clearing-path-for-scd411-commercialization 2026-07-27T06:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samchundang-pharm-reaches-global-settlement-in-eylea-biosimilar-patent-dispute-clearing-path-for-scd411-commercialization 2026-07-27T06:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/oliceridine-20-mg-kg-with-propofol-shows-optimal-balance-for-painless-gastroscopy-but-registry-discrepancies-raise-questions 2026-07-27T06:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oliceridine-20-mg-kg-with-propofol-shows-optimal-balance-for-painless-gastroscopy-but-registry-discrepancies-raise-questions 2026-07-27T06:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/dss-imagetech-charts-growth-path-through-ai-enabled-diagnostics-and-reproductive-care-expansion 2026-07-27T06:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dss-imagetech-charts-growth-path-through-ai-enabled-diagnostics-and-reproductive-care-expansion 2026-07-27T06:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/simvastatin-identified-as-promising-antibiotic-adjuvant-for-periodontitis-treatment 2026-07-27T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simvastatin-identified-as-promising-antibiotic-adjuvant-for-periodontitis-treatment 2026-07-27T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/imricor-launches-us-commercial-operations-with-first-northstar-radiation-free-cardiac-system-at-rady-children-s-hospital 2026-07-27T03:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imricor-launches-us-commercial-operations-with-first-northstar-radiation-free-cardiac-system-at-rady-children-s-hospital 2026-07-27T03:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/anthony-fauci-s-2020-diaries-reveal-preoccupation-with-media-fame-during-covid-19-pandemic 2026-07-27T03:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthony-fauci-s-2020-diaries-reveal-preoccupation-with-media-fame-during-covid-19-pandemic 2026-07-27T03:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/nrc-proposes-eliminating-50-year-alara-radiation-safety-principle-amid-nuclear-expansion-push 2026-07-27T02:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrc-proposes-eliminating-50-year-alara-radiation-safety-principle-amid-nuclear-expansion-push 2026-07-27T02:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/vietnamese-scientists-build-first-large-scale-population-specific-reference-genome-published-in-nature-communications 2026-07-27T02:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnamese-scientists-build-first-large-scale-population-specific-reference-genome-published-in-nature-communications 2026-07-27T02:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-ceo-dr-dajun-yang-ranked-no-3-on-the-medicine-maker-power-list-2026-in-small-molecules 2026-07-27T01:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-ceo-dr-dajun-yang-ranked-no-3-on-the-medicine-maker-power-list-2026-in-small-molecules 2026-07-27T01:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/seaweed-derived-fucoidan-demonstrates-clinically-significant-relief-of-bph-symptoms-in-randomized-trial 2026-07-27T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seaweed-derived-fucoidan-demonstrates-clinically-significant-relief-of-bph-symptoms-in-randomized-trial 2026-07-27T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/new-tick-data-for-credelio-quattro-strengthens-bullish-case-for-elanco-animal-health 2026-07-27T01:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-tick-data-for-credelio-quattro-strengthens-bullish-case-for-elanco-animal-health 2026-07-27T01:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/19f-nmr-reveals-hidden-bound-state-dynamics-of-sars-cov-2-3clpro-inhibitor-complexes-guiding-next-generation-antiviral-design 2026-07-27T00:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/19f-nmr-reveals-hidden-bound-state-dynamics-of-sars-cov-2-3clpro-inhibitor-complexes-guiding-next-generation-antiviral-design 2026-07-27T00:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/vector-science-therapeutics-reports-first-quarterly-results-targets-august-2026-revenue-from-peptide-manufacturing 2026-07-27T00:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vector-science-therapeutics-reports-first-quarterly-results-targets-august-2026-revenue-from-peptide-manufacturing 2026-07-27T00:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/tanruprubart-demonstrates-rapid-recovery-in-guillain-barre-syndrome-supporting-2026-bla-submission 2026-07-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tanruprubart-demonstrates-rapid-recovery-in-guillain-barre-syndrome-supporting-2026-bla-submission 2026-07-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mark-wildgust-on-culture-as-the-engine-of-oncology-innovation-at-johnson-johnson 2026-07-26T23:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mark-wildgust-on-culture-as-the-engine-of-oncology-innovation-at-johnson-johnson 2026-07-26T23:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-at-home-alzheimer-s-headset-spectris-nears-fda-decision-ochsner-health-prepares-for-louisiana-rollout 2026-07-26T22:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-at-home-alzheimer-s-headset-spectris-nears-fda-decision-ochsner-health-prepares-for-louisiana-rollout 2026-07-26T22:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/zimbabwe-s-black-market-arv-use-in-poultry-a-growing-public-health-threat 2026-07-26T22:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimbabwe-s-black-market-arv-use-in-poultry-a-growing-public-health-threat 2026-07-26T22:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/viral-menopause-cocktail-of-allergy-and-antacid-drugs-lacks-evidence-experts-warn 2026-07-26T20:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viral-menopause-cocktail-of-allergy-and-antacid-drugs-lacks-evidence-experts-warn 2026-07-26T20:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/ngs-uptake-remains-low-among-medicare-cancer-patients-despite-expanded-coverage-study-finds 2026-07-26T20:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ngs-uptake-remains-low-among-medicare-cancer-patients-despite-expanded-coverage-study-finds 2026-07-26T20:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-davunetide-slows-progression-of-rare-brain-disease-psp-in-women-reanalysis-reveals 2026-07-26T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-davunetide-slows-progression-of-rare-brain-disease-psp-in-women-reanalysis-reveals 2026-07-26T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/gallbladder-cancer-foundation-launches-expanded-digital-hub-with-ai-tools-financial-aid-and-virtual-support-for-patients-worldwide 2026-07-26T18:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gallbladder-cancer-foundation-launches-expanded-digital-hub-with-ai-tools-financial-aid-and-virtual-support-for-patients-worldwide 2026-07-26T18:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-buy-ratings-on-sino-biopharmaceutical-with-strong-upside-potential 2026-07-26T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-buy-ratings-on-sino-biopharmaceutical-with-strong-upside-potential 2026-07-26T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/geriatric-oncology-in-2040-from-evidence-to-implementation-as-the-next-frontier 2026-07-26T17:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geriatric-oncology-in-2040-from-evidence-to-implementation-as-the-next-frontier 2026-07-26T17:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/cayman-islands-confirms-infectious-coryza-outbreak-in-poultry-flocks-launches-vaccination-and-biosecurity-response 2026-07-26T17:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cayman-islands-confirms-infectious-coryza-outbreak-in-poultry-flocks-launches-vaccination-and-biosecurity-response 2026-07-26T17:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/horsefil-launches-gummy-dietary-supplement-featuring-amino-acid-and-botanical-blend 2026-07-26T17:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/horsefil-launches-gummy-dietary-supplement-featuring-amino-acid-and-botanical-blend 2026-07-26T17:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-gen-preclinical-translation-nams-humanized-mouse-models-and-ai-integration-take-center-stage-at-bio-asia-taiwan-2026 2026-07-26T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-gen-preclinical-translation-nams-humanized-mouse-models-and-ai-integration-take-center-stage-at-bio-asia-taiwan-2026 2026-07-26T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/msk-harnesses-ai-and-real-world-genomic-data-to-advance-lung-cancer-care 2026-07-26T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msk-harnesses-ai-and-real-world-genomic-data-to-advance-lung-cancer-care 2026-07-26T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-pushes-alzheimer-s-screening-while-uspstf-remains-paralyzed-for-over-a-year 2026-07-26T16:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-pushes-alzheimer-s-screening-while-uspstf-remains-paralyzed-for-over-a-year 2026-07-26T16:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/postpartum-psychosis-on-trial-the-lindsay-clancy-case-exposes-a-fragmented-maternal-mental-health-system 2026-07-26T14:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/postpartum-psychosis-on-trial-the-lindsay-clancy-case-exposes-a-fragmented-maternal-mental-health-system 2026-07-26T14:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/bystro-ai-a-conversational-genomics-platform-aims-to-democratize-genetic-data-analysis 2026-07-26T14:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bystro-ai-a-conversational-genomics-platform-aims-to-democratize-genetic-data-analysis 2026-07-26T14:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-next-new-three-ai-robotics-and-innovative-drugs-reshape-global-pharma-r-d-landscape 2026-07-26T11:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-next-new-three-ai-robotics-and-innovative-drugs-reshape-global-pharma-r-d-landscape 2026-07-26T11:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/first-known-transmissible-cancer-discovered-in-wild-freshwater-catfish 2026-07-26T09:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-known-transmissible-cancer-discovered-in-wild-freshwater-catfish 2026-07-26T09:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/hdac6-identified-as-biomarker-for-b-all-dissemination-and-relapse-risk 2026-07-26T08:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hdac6-identified-as-biomarker-for-b-all-dissemination-and-relapse-risk 2026-07-26T08:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/planetary-health-diet-linked-to-28-lower-cardiovascular-risk-in-postmenopausal-women 2026-07-26T08:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/planetary-health-diet-linked-to-28-lower-cardiovascular-risk-in-postmenopausal-women 2026-07-26T08:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-uncover-molecular-switch-linking-amino-acid-sensing-to-mtorc1-activation-opening-new-avenues-for-cancer-therapy 2026-07-26T08:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaist-researchers-uncover-molecular-switch-linking-amino-acid-sensing-to-mtorc1-activation-opening-new-avenues-for-cancer-therapy 2026-07-26T08:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/father-overcomes-hepatitis-c-and-fatty-liver-disease-to-become-living-donor-for-son-with-alagille-syndrome 2026-07-26T05:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/father-overcomes-hepatitis-c-and-fatty-liver-disease-to-become-living-donor-for-son-with-alagille-syndrome 2026-07-26T05:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/after-60-years-scientists-uncover-metformin-s-hidden-brain-effects-through-rap1-signaling 2026-07-26T05:13:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/after-60-years-scientists-uncover-metformin-s-hidden-brain-effects-through-rap1-signaling 2026-07-26T05:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/south-korean-doctors-arrested-for-illegal-narcotic-administration-and-patient-filming-police-urge-dexmedetomidine-regulation 2026-07-26T05:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korean-doctors-arrested-for-illegal-narcotic-administration-and-patient-filming-police-urge-dexmedetomidine-regulation 2026-07-26T05:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/anvisa-approves-clinical-trial-modifications-for-14-investigational-drugs-including-keytruda-and-novel-oncology-agents 2026-07-26T05:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anvisa-approves-clinical-trial-modifications-for-14-investigational-drugs-including-keytruda-and-novel-oncology-agents 2026-07-26T05:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/immune-ecosystem-remodeling-how-single-cell-spatial-omics-and-ai-are-redefining-precision-immunotherapy-in-cancer-and-infectious-diseases 2026-07-26T05:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-ecosystem-remodeling-how-single-cell-spatial-omics-and-ai-are-redefining-precision-immunotherapy-in-cancer-and-infectious-diseases 2026-07-26T05:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/whole-body-mri-scans-surge-in-popularity-despite-warnings-from-major-medical-organizations 2026-07-26T05:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whole-body-mri-scans-surge-in-popularity-despite-warnings-from-major-medical-organizations 2026-07-26T05:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/specific-gut-microbes-linked-to-changes-in-biological-aging-rates-study-finds 2026-07-26T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/specific-gut-microbes-linked-to-changes-in-biological-aging-rates-study-finds 2026-07-26T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/household-drinking-water-identified-as-major-source-of-long-term-lithium-exposure-in-western-u-s-tribal-communities 2026-07-26T00:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/household-drinking-water-identified-as-major-source-of-long-term-lithium-exposure-in-western-u-s-tribal-communities 2026-07-26T00:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/nba-and-chuka-university-sign-mou-to-strengthen-biosafety-education-and-research-in-kenya 2026-07-25T23:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nba-and-chuka-university-sign-mou-to-strengthen-biosafety-education-and-research-in-kenya 2026-07-25T23:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/avantor-s-nusil-expands-partnership-with-population-council-for-three-month-dapivirine-vaginal-ring-to-advance-hiv-prevention 2026-07-25T22:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avantor-s-nusil-expands-partnership-with-population-council-for-three-month-dapivirine-vaginal-ring-to-advance-hiv-prevention 2026-07-25T22:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/society-of-hematologic-oncology-launches-second-educational-podcast-soho-spotlight-on-hematologic-malignancy-management 2026-07-25T21:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/society-of-hematologic-oncology-launches-second-educational-podcast-soho-spotlight-on-hematologic-malignancy-management 2026-07-25T21:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-cas-acts-as-commander-in-chief-of-a-layered-bacterial-immune-network-nature-study-reveals 2026-07-25T21:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-cas-acts-as-commander-in-chief-of-a-layered-bacterial-immune-network-nature-study-reveals 2026-07-25T21:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-old-neuroblastoma-survivor-honored-at-uab-for-clinical-trial-participation-that-saved-her-life 2026-07-25T20:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-year-old-neuroblastoma-survivor-honored-at-uab-for-clinical-trial-participation-that-saved-her-life 2026-07-25T20:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-30-9-million-to-expand-the-neighborhoods-study-linking-social-exposome-to-alzheimer-s-disease-risk 2026-07-25T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-30-9-million-to-expand-the-neighborhoods-study-linking-social-exposome-to-alzheimer-s-disease-risk 2026-07-25T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/cryoport-reports-q2-2026-revenue-growth-of-8-achieves-positive-adjusted-ebitda-milestone 2026-07-25T19:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cryoport-reports-q2-2026-revenue-growth-of-8-achieves-positive-adjusted-ebitda-milestone 2026-07-25T19:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-rates-in-sub-saharan-africa-projected-to-more-than-double-by-2050-who-report-warns 2026-07-25T19:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-rates-in-sub-saharan-africa-projected-to-more-than-double-by-2050-who-report-warns 2026-07-25T19:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/ani-pharmaceuticals-draws-bullish-analyst-attention-following-positive-iluvien-developments 2026-07-25T19:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ani-pharmaceuticals-draws-bullish-analyst-attention-following-positive-iluvien-developments 2026-07-25T19:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/mrbeast-lebron-james-and-amgen-join-forces-to-launch-pediatric-cancer-dream-team-and-global-fundraising-campaign 2026-07-25T18:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrbeast-lebron-james-and-amgen-join-forces-to-launch-pediatric-cancer-dream-team-and-global-fundraising-campaign 2026-07-25T18:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-over-the-counter-fixed-dose-combination-of-acetaminophen-and-naproxen-for-pain-relief 2026-07-25T16:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-over-the-counter-fixed-dose-combination-of-acetaminophen-and-naproxen-for-pain-relief 2026-07-25T16:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/cold-chain-technologies-launches-ecoflex-xs-reusable-shipper-for-small-volume-clinical-trial-and-diagnostic-shipments 2026-07-25T16:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cold-chain-technologies-launches-ecoflex-xs-reusable-shipper-for-small-volume-clinical-trial-and-diagnostic-shipments 2026-07-25T16:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-doubles-order-book-to-ps65-million-as-integrated-clinical-development-platform-gains-traction 2026-07-25T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hvivo-doubles-order-book-to-ps65-million-as-integrated-clinical-development-platform-gains-traction 2026-07-25T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-s-apitoria-to-acquire-80-stake-in-a1-biochem-cro-for-17-million-building-integrated-crdmo-platform 2026-07-25T16:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-s-apitoria-to-acquire-80-stake-in-a1-biochem-cro-for-17-million-building-integrated-crdmo-platform 2026-07-25T16:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/updated-u-s-dietary-guidelines-raise-protein-recommendations-to-1-2-1-6-g-kg-day-but-experts-question-universal-application 2026-07-25T16:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-u-s-dietary-guidelines-raise-protein-recommendations-to-1-2-1-6-g-kg-day-but-experts-question-universal-application 2026-07-25T16:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-precision-medicine-in-sarcoma-tumor-organoids-and-ai-reshape-rare-cancer-care 2026-07-25T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-precision-medicine-in-sarcoma-tumor-organoids-and-ai-reshape-rare-cancer-care 2026-07-25T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/progranulin-and-jak2-stat3-synergy-identified-as-potential-target-to-overcome-differentiation-block-in-leukemia 2026-07-25T16:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/progranulin-and-jak2-stat3-synergy-identified-as-potential-target-to-overcome-differentiation-block-in-leukemia 2026-07-25T16:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/13-children-sickened-after-consuming-suspected-mushroom-laced-edibles-at-new-jersey-ymca-summer-camp 2026-07-25T15:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/13-children-sickened-after-consuming-suspected-mushroom-laced-edibles-at-new-jersey-ymca-summer-camp 2026-07-25T15:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/china-poaches-105-top-us-scientists-as-biotech-brain-drain-accelerates 2026-07-25T15:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-poaches-105-top-us-scientists-as-biotech-brain-drain-accelerates 2026-07-25T15:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/first-mrna-vaccine-and-neutralizing-antibodies-show-promise-against-emerging-bourbon-virus 2026-07-25T11:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-mrna-vaccine-and-neutralizing-antibodies-show-promise-against-emerging-bourbon-virus 2026-07-25T11:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-study-links-gut-microbe-byproduct-tmao-to-higher-risk-of-atrial-fibrillation 2026-07-25T08:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-study-links-gut-microbe-byproduct-tmao-to-higher-risk-of-atrial-fibrillation 2026-07-25T08:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/beckman-coulter-launches-fully-automated-dxu-1800-urinalysis-system-at-adlm-2026-to-address-rising-testing-demand 2026-07-25T08:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beckman-coulter-launches-fully-automated-dxu-1800-urinalysis-system-at-adlm-2026-to-address-rising-testing-demand 2026-07-25T08:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-trixeo-receives-chmp-recommendation-for-eu-approval-in-asthma 2026-07-25T08:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-trixeo-receives-chmp-recommendation-for-eu-approval-in-asthma 2026-07-25T08:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/bone-biologics-doubles-australian-trial-sites-for-nb1-spinal-fusion-study-targets-year-end-2026-enrollment 2026-07-25T07:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-biologics-doubles-australian-trial-sites-for-nb1-spinal-fusion-study-targets-year-end-2026-enrollment 2026-07-25T07:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/sildenafil-may-block-cancer-metastasis-by-trapping-cholesterol-preclinical-study-finds 2026-07-25T07:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sildenafil-may-block-cancer-metastasis-by-trapping-cholesterol-preclinical-study-finds 2026-07-25T07:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/california-reports-52-measles-cases-in-2026-more-than-double-2025-total-as-cdph-urges-back-to-school-vaccination 2026-07-25T06:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-reports-52-measles-cases-in-2026-more-than-double-2025-total-as-cdph-urges-back-to-school-vaccination 2026-07-25T06:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-in-addiction-treatment-but-experts-urge-caution 2026-07-25T05:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-promise-in-addiction-treatment-but-experts-urge-caution 2026-07-25T05:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/novabridge-to-report-first-half-2026-results-and-corporate-update-on-august-20 2026-07-25T04:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novabridge-to-report-first-half-2026-results-and-corporate-update-on-august-20 2026-07-25T04:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/allele-selective-aso-therapy-enables-teen-with-rare-scn2a-epilepsy-to-walk-for-the-first-time 2026-07-25T02:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allele-selective-aso-therapy-enables-teen-with-rare-scn2a-epilepsy-to-walk-for-the-first-time 2026-07-25T02:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-pharma-task-force-urges-three-month-deadline-to-cut-drug-access-delays-and-pricing-barriers 2026-07-25T00:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-pharma-task-force-urges-three-month-deadline-to-cut-drug-access-delays-and-pricing-barriers 2026-07-25T00:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-eu-approval-of-linerixibat-for-cholestatic-pruritus-in-primary-biliary-cholangitis 2026-07-25T00:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-eu-approval-of-linerixibat-for-cholestatic-pruritus-in-primary-biliary-cholangitis 2026-07-25T00:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/3d-resnet-deep-learning-model-classifies-cisplatin-response-in-colorectal-cancer-spheroids-using-oct-imaging 2026-07-24T23:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-resnet-deep-learning-model-classifies-cisplatin-response-in-colorectal-cancer-spheroids-using-oct-imaging 2026-07-24T23:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/american-regent-issues-nationwide-recall-of-papaverine-hydrochloride-injection-due-to-glass-and-paraformaldehyde-particulate-contamination 2026-07-24T23:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-regent-issues-nationwide-recall-of-papaverine-hydrochloride-injection-due-to-glass-and-paraformaldehyde-particulate-contamination 2026-07-24T23:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-reports-record-q2-revenue-and-expanding-manufacturing-backlog 2026-07-24T23:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmos-health-reports-record-q2-revenue-and-expanding-manufacturing-backlog 2026-07-24T23:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-s-brinsupri-launch-pace-raises-concerns-despite-strong-q2-prescription-trends 2026-07-24T23:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-s-brinsupri-launch-pace-raises-concerns-despite-strong-q2-prescription-trends 2026-07-24T23:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-scientists-solve-gipr-paradox-distinct-brain-circuits-explain-why-both-activating-and-blocking-the-same-receptor-drives-weight-loss 2026-07-24T23:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-scientists-solve-gipr-paradox-distinct-brain-circuits-explain-why-both-activating-and-blocking-the-same-receptor-drives-weight-loss 2026-07-24T23:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-transcriptomics-reveals-new-therapeutic-targets-for-severe-preeclampsia 2026-07-24T23:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-transcriptomics-reveals-new-therapeutic-targets-for-severe-preeclampsia 2026-07-24T23:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/bnt162b2-mrna-vaccine-demonstrates-strong-immunogenicity-and-favorable-safety-profile-in-adolescents-with-juvenile-immune-mediated-inflammatory-disease 2026-07-24T22:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bnt162b2-mrna-vaccine-demonstrates-strong-immunogenicity-and-favorable-safety-profile-in-adolescents-with-juvenile-immune-mediated-inflammatory-disease 2026-07-24T22:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/former-nfl-player-breiden-fehoko-alleges-covid-19-vaccine-side-effects-reignites-debate-over-league-s-pandemic-era-policies 2026-07-24T22:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-nfl-player-breiden-fehoko-alleges-covid-19-vaccine-side-effects-reignites-debate-over-league-s-pandemic-era-policies 2026-07-24T22:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/global-wellness-summit-2026-precision-longevity-women-s-health-and-neuroaesthetics-take-center-stage-at-landmark-20th-anniversary-conference 2026-07-24T22:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-wellness-summit-2026-precision-longevity-women-s-health-and-neuroaesthetics-take-center-stage-at-landmark-20th-anniversary-conference 2026-07-24T22:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/obesity-weakens-anti-tumor-immune-response-in-lung-cancer-but-exercise-may-restore-it 2026-07-24T19:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obesity-weakens-anti-tumor-immune-response-in-lung-cancer-but-exercise-may-restore-it 2026-07-24T19:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tylenol-with-naproxen-the-first-otc-fixed-dose-combination-of-acetaminophen-and-naproxen-sodium 2026-07-24T19:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tylenol-with-naproxen-the-first-otc-fixed-dose-combination-of-acetaminophen-and-naproxen-sodium 2026-07-24T19:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pseudomonas-aeruginosa-strains-emerge-as-significant-cause-of-utis-in-gulf-coast-region 2026-07-24T19:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pseudomonas-aeruginosa-strains-emerge-as-significant-cause-of-utis-in-gulf-coast-region 2026-07-24T19:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/salk-institute-identifies-acid-ceramidase-as-novel-driver-of-ferroptosis-vulnerability-in-senescent-cells-opening-path-to-healthy-aging-therapeutics 2026-07-24T19:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salk-institute-identifies-acid-ceramidase-as-novel-driver-of-ferroptosis-vulnerability-in-senescent-cells-opening-path-to-healthy-aging-therapeutics 2026-07-24T19:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/twist-bioscience-raises-fiscal-2026-guidance-as-ai-enabled-drug-discovery-demand-surges 2026-07-24T18:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/twist-bioscience-raises-fiscal-2026-guidance-as-ai-enabled-drug-discovery-demand-surges 2026-07-24T18:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/ai-is-already-transforming-oncology-drug-design-and-clinical-trials-astrazeneca-s-reis-filho-tells-aacr 2026-07-24T18:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-is-already-transforming-oncology-drug-design-and-clinical-trials-astrazeneca-s-reis-filho-tells-aacr 2026-07-24T18:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/community-rallies-to-fund-personalised-mrna-vaccine-for-three-year-old-australian-girl-with-dipg 2026-07-24T18:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-rallies-to-fund-personalised-mrna-vaccine-for-three-year-old-australian-girl-with-dipg 2026-07-24T18:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/ai-helps-stanford-scientists-discover-natural-ozempic-without-the-usual-side-effects 2026-07-24T18:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-helps-stanford-scientists-discover-natural-ozempic-without-the-usual-side-effects 2026-07-24T18:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-faces-analyst-scrutiny-ahead-of-q2-2026-earnings-amid-pipeline-challenges 2026-07-24T18:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-faces-analyst-scrutiny-ahead-of-q2-2026-earnings-amid-pipeline-challenges 2026-07-24T18:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/lipoic-acid-trisulfide-creates-super-hgf-that-doubles-muscle-repair-signaling-and-resists-age-related-damage 2026-07-24T17:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipoic-acid-trisulfide-creates-super-hgf-that-doubles-muscle-repair-signaling-and-resists-age-related-damage 2026-07-24T17:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committees-under-scrutiny-the-case-for-reform-after-capricor-s-deramiocel-review 2026-07-24T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committees-under-scrutiny-the-case-for-reform-after-capricor-s-deramiocel-review 2026-07-24T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/cycletrack-study-to-build-world-s-largest-menstrual-fluid-biobank-in-bid-to-transform-heavy-menstrual-bleeding-care 2026-07-24T17:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cycletrack-study-to-build-world-s-largest-menstrual-fluid-biobank-in-bid-to-transform-heavy-menstrual-bleeding-care 2026-07-24T17:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-vtama-cream-0-5-for-atopic-dermatitis-in-children-under-12 2026-07-24T16:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-vtama-cream-0-5-for-atopic-dermatitis-in-children-under-12 2026-07-24T16:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-of-first-in-class-adc-dyp688-shows-promising-activity-in-metastatic-uveal-melanoma 2026-07-24T16:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-of-first-in-class-adc-dyp688-shows-promising-activity-in-metastatic-uveal-melanoma 2026-07-24T16:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/dabrafenib-plus-trametinib-significantly-improves-pfs-in-braf-v600e-positive-advanced-thyroid-cancer 2026-07-24T15:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dabrafenib-plus-trametinib-significantly-improves-pfs-in-braf-v600e-positive-advanced-thyroid-cancer 2026-07-24T15:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-minoryx-s-nezglyal-as-first-pharmacological-treatment-for-pediatric-cerebral-adrenoleukodystrophy 2026-07-24T15:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-minoryx-s-nezglyal-as-first-pharmacological-treatment-for-pediatric-cerebral-adrenoleukodystrophy 2026-07-24T15:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-demonstrates-elivetm-platform-measures-cytotoxicity-in-targeted-therapies-expanding-functional-precision-medicine-reach 2026-07-24T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elephas-demonstrates-elivetm-platform-measures-cytotoxicity-in-targeted-therapies-expanding-functional-precision-medicine-reach 2026-07-24T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/who-searo-and-university-of-colombo-sign-agreement-to-scale-ai-enabled-precision-medicine-across-south-east-asia 2026-07-24T15:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-searo-and-university-of-colombo-sign-agreement-to-scale-ai-enabled-precision-medicine-across-south-east-asia 2026-07-24T15:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/removing-regnase-1-immune-brake-improves-car-t-cell-therapy-for-osteosarcoma 2026-07-24T15:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/removing-regnase-1-immune-brake-improves-car-t-cell-therapy-for-osteosarcoma 2026-07-24T15:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-fda-510-k-clearance-for-cobas-r-bv-cv-assay-bringing-pcr-precision-to-vaginitis-diagnosis 2026-07-24T14:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-receives-fda-510-k-clearance-for-cobas-r-bv-cv-assay-bringing-pcr-precision-to-vaginitis-diagnosis 2026-07-24T14:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-experts-demand-fda-drug-reviews-based-on-science-not-politics-amid-leadership-turmoil 2026-07-24T14:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-experts-demand-fda-drug-reviews-based-on-science-not-politics-amid-leadership-turmoil 2026-07-24T14:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/jubilant-biosys-convenes-2nd-edge-innovation-forum-uniting-biotech-founders-investors-and-pharma-leaders-to-accelerate-next-generation-therapies 2026-07-24T14:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jubilant-biosys-convenes-2nd-edge-innovation-forum-uniting-biotech-founders-investors-and-pharma-leaders-to-accelerate-next-generation-therapies 2026-07-24T14:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/estrella-immunopharma-doses-first-patient-in-starlight-1-dose-expansion-phase-for-eb103-artemis-t-cell-therapy-in-r-r-b-cell-nhl 2026-07-24T14:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estrella-immunopharma-doses-first-patient-in-starlight-1-dose-expansion-phase-for-eb103-artemis-t-cell-therapy-in-r-r-b-cell-nhl 2026-07-24T14:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-smart-healthcare-integrating-ai-and-iot-for-enhanced-patient-care-and-system-efficiency 2026-07-24T13:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-smart-healthcare-integrating-ai-and-iot-for-enhanced-patient-care-and-system-efficiency 2026-07-24T13:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/par-health-launches-first-and-only-generic-version-of-janumet-r-xr-in-the-united-states 2026-07-24T13:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/par-health-launches-first-and-only-generic-version-of-janumet-r-xr-in-the-united-states 2026-07-24T13:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/phoenix-nest-secures-1-49-million-nih-grant-to-advance-gene-therapy-manufacturing-for-sanfilippo-syndrome-type-c 2026-07-24T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phoenix-nest-secures-1-49-million-nih-grant-to-advance-gene-therapy-manufacturing-for-sanfilippo-syndrome-type-c 2026-07-24T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-revokes-orange-b-authorization-proposes-citrus-red-no-2-ban-in-push-to-eliminate-petroleum-based-food-dyes 2026-07-24T12:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-revokes-orange-b-authorization-proposes-citrus-red-no-2-ban-in-push-to-eliminate-petroleum-based-food-dyes 2026-07-24T12:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/oral-antiviral-ghp-88310-blocks-measles-transmission-in-ferret-model-paving-way-for-clinical-trials 2026-07-24T12:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-antiviral-ghp-88310-blocks-measles-transmission-in-ferret-model-paving-way-for-clinical-trials 2026-07-24T12:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/two-karolinska-institutet-researchers-awarded-wallenberg-proof-of-concept-funding-for-epigenomics-and-immunotherapy-innovations 2026-07-24T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-karolinska-institutet-researchers-awarded-wallenberg-proof-of-concept-funding-for-epigenomics-and-immunotherapy-innovations 2026-07-24T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/infinitopes-doses-first-patient-in-phase-i-iia-trial-of-off-the-shelf-cancer-vaccine-itop1-for-resectable-esophageal-adenocarcinoma 2026-07-24T11:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infinitopes-doses-first-patient-in-phase-i-iia-trial-of-off-the-shelf-cancer-vaccine-itop1-for-resectable-esophageal-adenocarcinoma 2026-07-24T11:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/onsite-mainstream-genetic-testing-doubles-brca-testing-rates-in-colorado-prostate-cancer-patients 2026-07-24T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onsite-mainstream-genetic-testing-doubles-brca-testing-rates-in-colorado-prostate-cancer-patients 2026-07-24T10:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-phase-iii-bold-trial-of-bylvay-in-biliary-atresia-misses-primary-endpoint 2026-07-24T06:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-phase-iii-bold-trial-of-bylvay-in-biliary-atresia-misses-primary-endpoint 2026-07-24T06:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/resonance-health-achieves-positive-operating-cash-flow-across-fy26-as-mri-liver-fibrosis-trial-advances 2026-07-24T06:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resonance-health-achieves-positive-operating-cash-flow-across-fy26-as-mri-liver-fibrosis-trial-advances 2026-07-24T06:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/oral-antibiotics-noninferior-to-iv-therapy-for-severe-pediatric-pneumonia-landmark-pedicap-trial-shows 2026-07-24T05:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-antibiotics-noninferior-to-iv-therapy-for-severe-pediatric-pneumonia-landmark-pedicap-trial-shows 2026-07-24T05:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/laminar-pharma-completes-lam561-phase-2b-3-trial-enrollment-in-newly-diagnosed-glioblastoma-topline-os-data-expected-q2-2027 2026-07-24T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laminar-pharma-completes-lam561-phase-2b-3-trial-enrollment-in-newly-diagnosed-glioblastoma-topline-os-data-expected-q2-2027 2026-07-24T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/superagers-exceptional-memory-cannot-be-explained-by-low-alzheimer-s-genetic-risk-study-finds 2026-07-24T03:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/superagers-exceptional-memory-cannot-be-explained-by-low-alzheimer-s-genetic-risk-study-finds 2026-07-24T03:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/patient-death-in-china-gene-editing-trial-raises-alarms-over-regulatory-oversight-and-transparency 2026-07-24T03:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-death-in-china-gene-editing-trial-raises-alarms-over-regulatory-oversight-and-transparency 2026-07-24T03:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-completes-all-cohort-dosing-in-australian-phase-i-trial-of-novel-long-acting-influenza-afc-drug-ak0406 2026-07-24T02:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-completes-all-cohort-dosing-in-australian-phase-i-trial-of-novel-long-acting-influenza-afc-drug-ak0406 2026-07-24T02:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-votes-against-compounding-emideltide-citing-safety-and-efficacy-concerns 2026-07-24T02:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-votes-against-compounding-emideltide-citing-safety-and-efficacy-concerns 2026-07-24T02:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/first-fully-integrated-smart-ring-monitors-glucose-ketone-and-other-biomarkers-in-sweat-simultaneously 2026-07-24T02:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-fully-integrated-smart-ring-monitors-glucose-ketone-and-other-biomarkers-in-sweat-simultaneously 2026-07-24T02:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/activation-capital-expands-virginia-bio-tech-center-doubling-wet-lab-capacity-to-accelerate-life-sciences-commercialization 2026-07-24T02:20:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/activation-capital-expands-virginia-bio-tech-center-doubling-wet-lab-capacity-to-accelerate-life-sciences-commercialization 2026-07-24T02:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/longer-less-fragmented-physical-activity-bouts-linked-to-lower-future-dementia-depression-and-anxiety-risk 2026-07-24T01:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longer-less-fragmented-physical-activity-bouts-linked-to-lower-future-dementia-depression-and-anxiety-risk 2026-07-24T01:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-reports-seventh-consecutive-profitable-half-year-driven-by-strategic-collaborations-and-ai-enabled-pipeline-advances 2026-07-24T01:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-reports-seventh-consecutive-profitable-half-year-driven-by-strategic-collaborations-and-ai-enabled-pipeline-advances 2026-07-24T01:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/11-year-old-becomes-first-uk-patient-to-receive-gene-therapy-for-bardet-biedl-syndrome-blindness 2026-07-24T01:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/11-year-old-becomes-first-uk-patient-to-receive-gene-therapy-for-bardet-biedl-syndrome-blindness 2026-07-24T01:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacy-students-gain-hands-on-advocacy-and-industry-experience-through-summer-internships 2026-07-24T00:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacy-students-gain-hands-on-advocacy-and-industry-experience-through-summer-internships 2026-07-24T00:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-bioe3-policy-drives-over-270-biomanufacturing-projects-and-15-bio-ai-hubs-nationwide 2026-07-24T00:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-bioe3-policy-drives-over-270-biomanufacturing-projects-and-15-bio-ai-hubs-nationwide 2026-07-24T00:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/pitchmi-selects-20-michigan-startups-to-compete-for-2-million-in-funding 2026-07-23T23:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pitchmi-selects-20-michigan-startups-to-compete-for-2-million-in-funding 2026-07-23T23:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/sphingotec-to-present-new-penkid-sepsis-data-and-co-host-sepsis-symposium-at-esicm-lives-2026 2026-07-23T23:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sphingotec-to-present-new-penkid-sepsis-data-and-co-host-sepsis-symposium-at-esicm-lives-2026 2026-07-23T23:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/alps-dx-to-debut-xpressor-filtration-and-capping-device-at-adlm-2026-targeting-preanalytical-bottlenecks-in-oral-fluid-testing 2026-07-23T22:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alps-dx-to-debut-xpressor-filtration-and-capping-device-at-adlm-2026-targeting-preanalytical-bottlenecks-in-oral-fluid-testing 2026-07-23T22:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/hyundai-hope-on-wheels-funds-two-pediatric-aml-research-programs-targeting-relapse-and-treatment-resistance 2026-07-23T22:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyundai-hope-on-wheels-funds-two-pediatric-aml-research-programs-targeting-relapse-and-treatment-resistance 2026-07-23T22:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/simbiosys-and-ferrum-health-partner-to-expand-access-to-fda-cleared-ai-surgical-planning-platform-for-breast-cancer 2026-07-23T21:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simbiosys-and-ferrum-health-partner-to-expand-access-to-fda-cleared-ai-surgical-planning-platform-for-breast-cancer 2026-07-23T21:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-epoch-study-finds-socioeconomic-position-outweighs-parental-health-behaviors-in-child-health-outcomes 2026-07-23T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-epoch-study-finds-socioeconomic-position-outweighs-parental-health-behaviors-in-child-health-outcomes 2026-07-23T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-how-dna-misfolding-causes-congenital-heart-disease 2026-07-23T20:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-how-dna-misfolding-causes-congenital-heart-disease 2026-07-23T20:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/omada-health-to-report-second-quarter-2026-financial-results-on-august-6 2026-07-23T20:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omada-health-to-report-second-quarter-2026-financial-results-on-august-6 2026-07-23T20:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/biobuilder-awarded-1-million-mlsc-grant-for-ai-powered-biotechnology-training-in-massachusetts-high-schools 2026-07-23T20:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biobuilder-awarded-1-million-mlsc-grant-for-ai-powered-biotechnology-training-in-massachusetts-high-schools 2026-07-23T20:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/white-house-ostp-proposes-sweeping-overhaul-of-federal-research-funding-shifting-focus-from-universities-to-industry-and-ai 2026-07-23T20:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/white-house-ostp-proposes-sweeping-overhaul-of-federal-research-funding-shifting-focus-from-universities-to-industry-and-ai 2026-07-23T20:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-completes-amicus-therapeutics-acquisition-expanding-rare-disease-portfolio-in-fabry-and-pompe 2026-07-23T19:13:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-completes-amicus-therapeutics-acquisition-expanding-rare-disease-portfolio-in-fabry-and-pompe 2026-07-23T19:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-20-million-to-northwestern-for-nation-s-first-ai-powered-protein-engineering-cloud-lab 2026-07-23T19:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-20-million-to-northwestern-for-nation-s-first-ai-powered-protein-engineering-cloud-lab 2026-07-23T19:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/lilac-biosciences-and-soin-neuroscience-publish-clinical-review-on-rna-biomarkers-for-objective-neuropathic-pain-assessment 2026-07-23T19:12:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilac-biosciences-and-soin-neuroscience-publish-clinical-review-on-rna-biomarkers-for-objective-neuropathic-pain-assessment 2026-07-23T19:12:17+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-blocks-drugmakers-unilateral-340b-rebate-models-preserving-upfront-discounts-for-safety-net-hospitals 2026-07-23T19:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-blocks-drugmakers-unilateral-340b-rebate-models-preserving-upfront-discounts-for-safety-net-hospitals 2026-07-23T19:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/endometriosis-a-systemic-inflammatory-disease-still-plagued-by-diagnostic-delays-and-underfunded-research 2026-07-23T19:11:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endometriosis-a-systemic-inflammatory-disease-still-plagued-by-diagnostic-delays-and-underfunded-research 2026-07-23T19:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/thyora-therapeutics-launches-with-novel-covalent-chemistry-platform-to-target-undruggable-disease-proteins 2026-07-23T19:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thyora-therapeutics-launches-with-novel-covalent-chemistry-platform-to-target-undruggable-disease-proteins 2026-07-23T19:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/brainstorm-advances-nurown-toward-phase-3b-endurance-trial-in-als-under-first-ever-spa-for-an-als-therapeutic 2026-07-23T19:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainstorm-advances-nurown-toward-phase-3b-endurance-trial-in-als-under-first-ever-spa-for-an-als-therapeutic 2026-07-23T19:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/precision-diabetes-and-nagase-diagnostics-announce-exclusive-u-s-commercialization-partnership-for-lucica-r-glycated-albumin-l-the-only-fda-cleared-glycated-albumin-assay 2026-07-23T19:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-diabetes-and-nagase-diagnostics-announce-exclusive-u-s-commercialization-partnership-for-lucica-r-glycated-albumin-l-the-only-fda-cleared-glycated-albumin-assay 2026-07-23T19:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/paddington-life-sciences-to-lead-london-wide-life-sciences-talent-hub-backed-by-ps3-2-million-mayoral-investment 2026-07-23T18:09:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paddington-life-sciences-to-lead-london-wide-life-sciences-talent-hub-backed-by-ps3-2-million-mayoral-investment 2026-07-23T18:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/norway-s-health-system-renews-nationwide-adoption-of-wolters-kluwer-uptodate-enterprise-edition-adding-ai-powered-clinical-decision-support 2026-07-23T18:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norway-s-health-system-renews-nationwide-adoption-of-wolters-kluwer-uptodate-enterprise-edition-adding-ai-powered-clinical-decision-support 2026-07-23T18:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-lantus-solostar-insulin-pen-faces-intermittent-supply-disruptions-across-the-u-s-amid-rising-demand 2026-07-23T18:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-lantus-solostar-insulin-pen-faces-intermittent-supply-disruptions-across-the-u-s-amid-rising-demand 2026-07-23T18:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/west-pharmaceutical-raises-2026-profit-forecast-on-surging-demand-for-injectable-drug-components-driven-by-glp-1-boom 2026-07-23T18:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-pharmaceutical-raises-2026-profit-forecast-on-surging-demand-for-injectable-drug-components-driven-by-glp-1-boom 2026-07-23T18:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/abelzeta-and-astrazeneca-s-armored-gpc3-car-t-therapy-shows-promising-efficacy-in-advanced-hepatocellular-carcinoma-published-in-nature 2026-07-23T18:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abelzeta-and-astrazeneca-s-armored-gpc3-car-t-therapy-shows-promising-efficacy-in-advanced-hepatocellular-carcinoma-published-in-nature 2026-07-23T18:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/alabama-teenager-will-roberts-whose-viral-plea-for-bone-cancer-drug-captured-national-attention-dies-at-15 2026-07-23T18:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alabama-teenager-will-roberts-whose-viral-plea-for-bone-cancer-drug-captured-national-attention-dies-at-15 2026-07-23T18:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-appoints-victor-dzau-pioneer-of-ace-inhibitor-research-to-board-of-directors 2026-07-23T18:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-appoints-victor-dzau-pioneer-of-ace-inhibitor-research-to-board-of-directors 2026-07-23T18:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/donor-derived-cell-free-dna-emerges-as-leading-biomarker-in-kidney-transplant-rejection-surveillance-market-to-reach-3-98-billion-by-2036 2026-07-23T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/donor-derived-cell-free-dna-emerges-as-leading-biomarker-in-kidney-transplant-rejection-surveillance-market-to-reach-3-98-billion-by-2036 2026-07-23T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/midwest-poultry-services-recalls-nearly-1-6-million-dozen-eggs-across-gulf-states-over-salmonella-risk 2026-07-23T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/midwest-poultry-services-recalls-nearly-1-6-million-dozen-eggs-across-gulf-states-over-salmonella-risk 2026-07-23T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-invests-additional-300-million-in-new-jersey-manufacturing-campus-total-commitment-surpasses-1-billion 2026-07-23T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-invests-additional-300-million-in-new-jersey-manufacturing-campus-total-commitment-surpasses-1-billion 2026-07-23T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/vyne-therapeutics-and-yarrow-bioscience-merger-nears-completion-cash-dividend-distributed-reverse-stock-split-set-and-yb-101-poised-to-advance-autoimmune-thyroid-disease-pipeline 2026-07-23T16:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyne-therapeutics-and-yarrow-bioscience-merger-nears-completion-cash-dividend-distributed-reverse-stock-split-set-and-yb-101-poised-to-advance-autoimmune-thyroid-disease-pipeline 2026-07-23T16:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-clinical-study-demonstrates-feasibility-of-fluorescence-imaging-in-orthopaedic-surgery 2026-07-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-clinical-study-demonstrates-feasibility-of-fluorescence-imaging-in-orthopaedic-surgery 2026-07-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/trialbee-appoints-michael-meerovich-as-cfo-to-drive-ai-powered-clinical-trial-recruitment-expansion 2026-07-23T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trialbee-appoints-michael-meerovich-as-cfo-to-drive-ai-powered-clinical-trial-recruitment-expansion 2026-07-23T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-drug-development-in-the-uk-25-year-analysis-reveals-shifting-trial-landscape-and-regulatory-reboot 2026-07-23T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-drug-development-in-the-uk-25-year-analysis-reveals-shifting-trial-landscape-and-regulatory-reboot 2026-07-23T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-targets-calr-mutation-driving-rare-blood-cancers 2026-07-23T16:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-targets-calr-mutation-driving-rare-blood-cancers 2026-07-23T16:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/intravenous-iron-drugs-market-projected-to-reach-us-7-4-billion-by-2034 2026-07-23T16:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intravenous-iron-drugs-market-projected-to-reach-us-7-4-billion-by-2034 2026-07-23T16:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-survivors-and-providers-show-significant-gaps-in-medical-cannabis-risk-awareness-and-communication-vcu-study-finds 2026-07-23T16:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-survivors-and-providers-show-significant-gaps-in-medical-cannabis-risk-awareness-and-communication-vcu-study-finds 2026-07-23T16:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/niki-biosolutions-enters-strategic-agreement-to-provide-apoe-genotyping-services-for-progressive-medical-research 2026-07-23T16:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niki-biosolutions-enters-strategic-agreement-to-provide-apoe-genotyping-services-for-progressive-medical-research 2026-07-23T16:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-technique-improves-targeted-therapy-delivery-for-malignant-brain-tumors 2026-07-23T16:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-guided-technique-improves-targeted-therapy-delivery-for-malignant-brain-tumors 2026-07-23T16:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-launches-eur200m-corporate-venture-fund-to-tap-early-stage-healthcare-innovation 2026-07-23T16:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-launches-eur200m-corporate-venture-fund-to-tap-early-stage-healthcare-innovation 2026-07-23T16:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-lifts-full-year-guidance-as-h1-2026-sales-surge-24-6-to-3-13-billion 2026-07-23T16:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-lifts-full-year-guidance-as-h1-2026-sales-surge-24-6-to-3-13-billion 2026-07-23T16:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/aavantgarde-cso-prof-alberto-auricchio-to-present-advances-in-aav-gene-therapy-for-inherited-retinal-diseases-at-jsgct-2026 2026-07-23T16:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aavantgarde-cso-prof-alberto-auricchio-to-present-advances-in-aav-gene-therapy-for-inherited-retinal-diseases-at-jsgct-2026 2026-07-23T16:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/kiniksa-raises-arcalyst-guidance-to-995m-as-kpl-387-advances-into-pivotal-phase-3-for-recurrent-pericarditis 2026-07-23T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiniksa-raises-arcalyst-guidance-to-995m-as-kpl-387-advances-into-pivotal-phase-3-for-recurrent-pericarditis 2026-07-23T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/synaptiq-therapeutics-launches-with-acquisition-of-syn-001-a-phase-ii-ready-small-molecule-for-22q11-2-deletion-syndrome 2026-07-23T15:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synaptiq-therapeutics-launches-with-acquisition-of-syn-001-a-phase-ii-ready-small-molecule-for-22q11-2-deletion-syndrome 2026-07-23T15:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/protein-maxxing-obsession-debunked-experts-warn-excess-protein-offers-little-benefit-and-may-harm 2026-07-23T14:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protein-maxxing-obsession-debunked-experts-warn-excess-protein-offers-little-benefit-and-may-harm 2026-07-23T14:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-doses-first-patient-in-phase-1-trial-of-cd25-targeting-adc-bat8013-for-advanced-solid-tumors 2026-07-23T14:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-solutions-doses-first-patient-in-phase-1-trial-of-cd25-targeting-adc-bat8013-for-advanced-solid-tumors 2026-07-23T14:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-secures-uspto-notice-of-allowance-for-biomarker-guided-patent-on-lp-184-in-multiple-solid-tumors 2026-07-23T14:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-secures-uspto-notice-of-allowance-for-biomarker-guided-patent-on-lp-184-in-multiple-solid-tumors 2026-07-23T14:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/r-d-portfolio-prioritization-emerges-as-critical-lever-as-pharma-faces-patent-cliff-and-capital-constraints 2026-07-23T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r-d-portfolio-prioritization-emerges-as-critical-lever-as-pharma-faces-patent-cliff-and-capital-constraints 2026-07-23T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-q3-2026-report-us-biosimilar-market-reaches-96-approvals-47-average-market-share 2026-07-23T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-q3-2026-report-us-biosimilar-market-reaches-96-approvals-47-average-market-share 2026-07-23T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/functional-mushroom-products-outpace-clinical-evidence-experts-caution 2026-07-23T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/functional-mushroom-products-outpace-clinical-evidence-experts-caution 2026-07-23T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-and-white-house-launch-clinical-ai-standards-sprint-with-closed-door-industry-demos 2026-07-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-and-white-house-launch-clinical-ai-standards-sprint-with-closed-door-industry-demos 2026-07-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/pmwc-joins-life-science-connect-to-expand-precision-medicine-community-engagement-year-round 2026-07-23T12:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmwc-joins-life-science-connect-to-expand-precision-medicine-community-engagement-year-round 2026-07-23T12:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/russia-s-first-trametinib-generic-hits-market-as-promomed-challenges-novartis-mekinist 2026-07-23T12:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-s-first-trametinib-generic-hits-market-as-promomed-challenges-novartis-mekinist 2026-07-23T12:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-of-rapamycin-reverses-autism-like-symptoms-in-adult-mice-within-hours-ucla-study-finds 2026-07-23T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-of-rapamycin-reverses-autism-like-symptoms-in-adult-mice-within-hours-ucla-study-finds 2026-07-23T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/newly-released-documents-reveal-fbi-intervened-to-block-questioning-of-covid-researcher-peter-daszak 2026-07-23T12:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newly-released-documents-reveal-fbi-intervened-to-block-questioning-of-covid-researcher-peter-daszak 2026-07-23T12:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/curcumin-shows-best-balance-of-anticancer-activity-and-safety-against-fibrosarcoma-cells-in-comparative-study 2026-07-23T12:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curcumin-shows-best-balance-of-anticancer-activity-and-safety-against-fibrosarcoma-cells-in-comparative-study 2026-07-23T12:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/easier-biologic-access-linked-to-higher-remission-rates-in-severe-asthma-global-study-finds 2026-07-23T10:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/easier-biologic-access-linked-to-higher-remission-rates-in-severe-asthma-global-study-finds 2026-07-23T10:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/dassault-systemes-to-acquire-arisglobal-for-1-8-billion-building-unified-ai-platform-for-life-sciences 2026-07-23T10:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dassault-systemes-to-acquire-arisglobal-for-1-8-billion-building-unified-ai-platform-for-life-sciences 2026-07-23T10:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-selects-navan-s-ai-powered-platform-to-unify-global-travel-and-expense-management 2026-07-23T10:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-selects-navan-s-ai-powered-platform-to-unify-global-travel-and-expense-management 2026-07-23T10:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/sknv-licenses-washington-university-immunotherapy-patent-for-fluorouracil-calcipotriene-combination-in-actinic-keratosis 2026-07-23T09:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sknv-licenses-washington-university-immunotherapy-patent-for-fluorouracil-calcipotriene-combination-in-actinic-keratosis 2026-07-23T09:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/ancient-immune-protein-c3-boosts-cancer-immunotherapy-when-produced-inside-tumors 2026-07-23T08:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ancient-immune-protein-c3-boosts-cancer-immunotherapy-when-produced-inside-tumors 2026-07-23T08:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/venus-medtech-completes-enrollment-in-prevails-pivotal-trial-for-fully-retrievable-tavr-device-venus-powerx 2026-07-23T08:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venus-medtech-completes-enrollment-in-prevails-pivotal-trial-for-fully-retrievable-tavr-device-venus-powerx 2026-07-23T08:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-advances-desidustat-into-phase-iii-sickle-cell-trial-in-partnership-with-icmr 2026-07-23T08:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-advances-desidustat-into-phase-iii-sickle-cell-trial-in-partnership-with-icmr 2026-07-23T08:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/zarpet-family-foundation-s-12-million-gift-fuels-polycystic-kidney-disease-research-at-cu-anschutz 2026-07-23T07:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zarpet-family-foundation-s-12-million-gift-fuels-polycystic-kidney-disease-research-at-cu-anschutz 2026-07-23T07:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/derriford-hospital-tops-uk-clinical-trial-recruitment-rankings-with-over-45000-patients-enrolled 2026-07-23T07:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/derriford-hospital-tops-uk-clinical-trial-recruitment-rankings-with-over-45000-patients-enrolled 2026-07-23T07:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/arkansas-attorney-general-sues-22-drug-companies-over-alleged-340b-discount-restrictions 2026-07-23T06:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkansas-attorney-general-sues-22-drug-companies-over-alleged-340b-discount-restrictions 2026-07-23T06:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/raps-names-2026-fellows-recognizing-leaders-in-rare-disease-and-regulatory-affairs 2026-07-23T05:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raps-names-2026-fellows-recognizing-leaders-in-rare-disease-and-regulatory-affairs 2026-07-23T05:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/sparrow-pharmaceuticals-bets-cortisol-not-glp-1-is-the-next-frontier-in-type-2-diabetes 2026-07-23T04:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparrow-pharmaceuticals-bets-cortisol-not-glp-1-is-the-next-frontier-in-type-2-diabetes 2026-07-23T04:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-linked-to-56-lower-risk-of-adult-onset-seizures-in-type-2-diabetes-patients 2026-07-23T04:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-linked-to-56-lower-risk-of-adult-onset-seizures-in-type-2-diabetes-patients 2026-07-23T04:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-background-shapes-cancer-evolution-trajectory-despite-identical-risk-factors-landmark-mouse-study-reveals 2026-07-23T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-background-shapes-cancer-evolution-trajectory-despite-identical-risk-factors-landmark-mouse-study-reveals 2026-07-23T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-unveils-automated-mass-spectrometry-ngs-platform-and-alzheimer-s-blood-test-at-adlm-2026 2026-07-23T02:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-unveils-automated-mass-spectrometry-ngs-platform-and-alzheimer-s-blood-test-at-adlm-2026 2026-07-23T02:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/secondary-care-gap-tied-to-racial-disparities-in-prostate-cancer-mortality 2026-07-23T02:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secondary-care-gap-tied-to-racial-disparities-in-prostate-cancer-mortality 2026-07-23T02:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-increased-hair-loss-risk-in-type-2-diabetes-study-finds 2026-07-23T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-increased-hair-loss-risk-in-type-2-diabetes-study-finds 2026-07-23T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/bd-president-dr-michael-garrison-to-retire-after-two-decades-biopharma-systems-to-report-directly-to-ceo 2026-07-23T01:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-president-dr-michael-garrison-to-retire-after-two-decades-biopharma-systems-to-report-directly-to-ceo 2026-07-23T01:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/portal-innovations-opens-new-jersey-innovation-hub-at-helix-with-16-founding-biotech-companies 2026-07-23T00:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portal-innovations-opens-new-jersey-innovation-hub-at-helix-with-16-founding-biotech-companies 2026-07-23T00:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/usp-to-open-biopharma-analytical-innovation-summit-with-plenary-on-monoclonal-antibody-standards 2026-07-23T00:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usp-to-open-biopharma-analytical-innovation-summit-with-plenary-on-monoclonal-antibody-standards 2026-07-23T00:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-auckland-establishes-new-department-of-cancer-sciences-advancing-vision-for-comprehensive-cancer-centre 2026-07-23T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-auckland-establishes-new-department-of-cancer-sciences-advancing-vision-for-comprehensive-cancer-centre 2026-07-23T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/cheiron-raises-8m-seed-round-to-build-ai-native-operating-system-for-drug-development-programs 2026-07-23T00:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cheiron-raises-8m-seed-round-to-build-ai-native-operating-system-for-drug-development-programs 2026-07-23T00:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/concurrent-palliative-care-remains-underused-among-young-adults-with-advanced-cancer-despite-doubling-over-13-years 2026-07-22T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concurrent-palliative-care-remains-underused-among-young-adults-with-advanced-cancer-despite-doubling-over-13-years 2026-07-22T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-untitled-letters-to-sanofi-and-viatris-over-misleading-drug-promotions 2026-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-untitled-letters-to-sanofi-and-viatris-over-misleading-drug-promotions 2026-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/methylation-mesa-define-functional-regulatory-elements-for-targeted-gene-activation 2026-07-22T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/methylation-mesa-define-functional-regulatory-elements-for-targeted-gene-activation 2026-07-22T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/boebert-introduces-botanical-drug-development-act-of-2026-to-support-fda-regulated-botanical-therapies 2026-07-22T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boebert-introduces-botanical-drug-development-act-of-2026-to-support-fda-regulated-botanical-therapies 2026-07-22T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/gut-derived-regulatory-b-cells-may-explain-efficacy-of-ms-immunotherapy 2026-07-22T20:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-derived-regulatory-b-cells-may-explain-efficacy-of-ms-immunotherapy 2026-07-22T20:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-langone-study-links-glyphosate-exposure-during-mid-pregnancy-to-increased-preterm-birth-risk 2026-07-22T20:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-langone-study-links-glyphosate-exposure-during-mid-pregnancy-to-increased-preterm-birth-risk 2026-07-22T20:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-recognized-among-industry-leaders-for-sustainable-biopharma-practices 2026-07-22T20:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-recognized-among-industry-leaders-for-sustainable-biopharma-practices 2026-07-22T20:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/arcstone-kingswood-names-karen-sterling-phd-cfa-as-head-of-biotechnology-investment-banking 2026-07-22T19:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcstone-kingswood-names-karen-sterling-phd-cfa-as-head-of-biotechnology-investment-banking 2026-07-22T19:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/structures-and-nucleotide-analog-inhibition-of-the-cchfv-polymerase-reveal-sofosbuvir-like-compounds-as-potent-chain-terminators 2026-07-22T19:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structures-and-nucleotide-analog-inhibition-of-the-cchfv-polymerase-reveal-sofosbuvir-like-compounds-as-potent-chain-terminators 2026-07-22T19:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/transcripta-bio-raises-24-million-to-advance-ai-powered-drug-discovery-platform-for-neurological-and-neuromuscular-diseases 2026-07-22T19:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcripta-bio-raises-24-million-to-advance-ai-powered-drug-discovery-platform-for-neurological-and-neuromuscular-diseases 2026-07-22T19:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/us-5-million-partnership-to-accelerate-minimally-invasive-biomarker-development-for-parkinson-s-and-alzheimer-s-disease 2026-07-22T19:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-5-million-partnership-to-accelerate-minimally-invasive-biomarker-development-for-parkinson-s-and-alzheimer-s-disease 2026-07-22T19:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/4th-dzg-munich-day-2026-ai-driven-drug-repurposing-takes-center-stage-at-munich-health-research-summit 2026-07-22T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4th-dzg-munich-day-2026-ai-driven-drug-repurposing-takes-center-stage-at-munich-health-research-summit 2026-07-22T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-tech-transfer-in-cell-therapy-navigating-the-critical-path-from-development-to-gmp-manufacturing 2026-07-22T18:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-tech-transfer-in-cell-therapy-navigating-the-critical-path-from-development-to-gmp-manufacturing 2026-07-22T18:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/nabp-launches-pulse-digital-platform-for-dispensers-to-strengthen-drug-supply-chain-security-and-dscsa-compliance 2026-07-22T18:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nabp-launches-pulse-digital-platform-for-dispensers-to-strengthen-drug-supply-chain-security-and-dscsa-compliance 2026-07-22T18:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/sfu-chemists-develop-light-driven-method-to-rapidly-generate-nucleoside-analog-libraries-accelerating-antiviral-drug-discovery 2026-07-22T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sfu-chemists-develop-light-driven-method-to-rapidly-generate-nucleoside-analog-libraries-accelerating-antiviral-drug-discovery 2026-07-22T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/formation-bio-appoints-michael-ehlers-as-chief-scientific-officer-and-head-of-r-d 2026-07-22T17:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formation-bio-appoints-michael-ehlers-as-chief-scientific-officer-and-head-of-r-d 2026-07-22T17:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-institute-of-new-jersey-elects-bayer-s-chuck-leitgeb-as-board-chair 2026-07-22T17:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-institute-of-new-jersey-elects-bayer-s-chuck-leitgeb-as-board-chair 2026-07-22T17:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/chicago-bears-host-inaugural-alumni-wellness-weekend-with-novartis-emphasizing-early-detection-and-mental-health 2026-07-22T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chicago-bears-host-inaugural-alumni-wellness-weekend-with-novartis-emphasizing-early-detection-and-mental-health 2026-07-22T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/one-in-four-u-s-workers-report-job-lock-due-to-health-insurance-marking-sharp-rise-since-2021 2026-07-22T17:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-in-four-u-s-workers-report-job-lock-due-to-health-insurance-marking-sharp-rise-since-2021 2026-07-22T17:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/william-shatner-and-daughter-both-declared-cancer-free-after-concurrent-stage-4-cancer-battles-highlighting-advances-in-immunotherapy-and-her2-targeted-treatment 2026-07-22T16:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/william-shatner-and-daughter-both-declared-cancer-free-after-concurrent-stage-4-cancer-battles-highlighting-advances-in-immunotherapy-and-her2-targeted-treatment 2026-07-22T16:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-oral-vitamin-d-shows-rapid-relief-for-cancer-therapy-induced-skin-toxicities 2026-07-22T16:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-oral-vitamin-d-shows-rapid-relief-for-cancer-therapy-induced-skin-toxicities 2026-07-22T16:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/fsu-colleges-of-nursing-and-medicine-awarded-1-6m-nih-grant-to-train-nurse-scientists-in-digital-health-and-ai 2026-07-22T16:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fsu-colleges-of-nursing-and-medicine-awarded-1-6m-nih-grant-to-train-nurse-scientists-in-digital-health-and-ai 2026-07-22T16:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/texas-h-1b-visa-restrictions-threaten-cancer-research-momentum-at-md-anderson 2026-07-22T15:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-h-1b-visa-restrictions-threaten-cancer-research-momentum-at-md-anderson 2026-07-22T15:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/science-corp-launches-prima-first-ce-marked-bci-implant-for-vision-restoration-in-dry-amd 2026-07-22T15:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/science-corp-launches-prima-first-ce-marked-bci-implant-for-vision-restoration-in-dry-amd 2026-07-22T15:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/kalamazoo-county-board-weighs-cutting-glp-1-obesity-drug-coverage-as-prescription-costs-surge-past-1-5-million 2026-07-22T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalamazoo-county-board-weighs-cutting-glp-1-obesity-drug-coverage-as-prescription-costs-surge-past-1-5-million 2026-07-22T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/in-utero-gene-therapy-trial-targets-gm1-gangliosidosis-before-birth 2026-07-22T15:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-utero-gene-therapy-trial-targets-gm1-gangliosidosis-before-birth 2026-07-22T15:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/repligen-to-acquire-biolife-solutions-in-1-5-billion-deal-expanding-into-cell-therapy-market 2026-07-22T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repligen-to-acquire-biolife-solutions-in-1-5-billion-deal-expanding-into-cell-therapy-market 2026-07-22T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/genetically-engineered-american-chestnut-clears-first-federal-regulatory-hurdle-toward-restoration 2026-07-22T14:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetically-engineered-american-chestnut-clears-first-federal-regulatory-hurdle-toward-restoration 2026-07-22T14:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-and-latch-medical-forge-strategic-alliance-to-combine-ai-powered-cgm-biosensing-with-intradermal-drug-delivery-for-metabolic-disease 2026-07-22T14:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-and-latch-medical-forge-strategic-alliance-to-combine-ai-powered-cgm-biosensing-with-intradermal-drug-delivery-for-metabolic-disease 2026-07-22T14:07:20+00:00 hourly 0.9